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ABSTRACT
Immunosignaturing is a medical test for assessing the health status of a patient by
applying microarrays of random sequence peptides to determine the patient’s immune
fingerprint by associating antibodies from a biological sample to immune responses.
The immunosignature measurements can potentially provide pre-symptomatic diag-
nosis for infectious diseases or detection of biological threats. Currently, traditional
bioinformatics tools, such as data mining classification algorithms, are used to pro-
cess the large amount of peptide microarray data. However, these methods generally
require training data and do not adapt to changing immune conditions or additional
patient information.
This work proposes advanced processing techniques to improve the classification
and identification of single and multiple underlying immune response states embed-
ded in immunosignatures, making it possible to detect both known and previously
unknown diseases or biothreat agents. Novel adaptive learning methodologies for un-
supervised and semi-supervised clustering integrated with immunosignature feature
extraction approaches are proposed. The techniques are based on extracting novel
stochastic features from microarray binding intensities and use Dirichlet process Gaus-
sian mixture models to adaptively cluster the immunosignatures in the feature space.
This learning-while-clustering approach allows continuous discovery of antibody ac-
tivity by adaptively detecting new disease states, with limited a priori disease or
patient information. A beta process factor analysis model to determine underlying
patient immune responses is also proposed to further improve the adaptive clustering
performance by formatting new relationships between patients and antibody activ-
ity. In order to extend the clustering methods for diagnosing multiple states in a
patient, the adaptive hierarchical Dirichlet process is integrated with modified beta
process factor analysis latent feature modeling to identify relationships between pa-
i
tients and infectious agents. The use of Bayesian nonparametric adaptive learning
techniques allows for further clustering if additional patient data is received. Sig-
nificant improvements in feature identification and immune response clustering are
demonstrated using samples from patients with different diseases.
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Chapter 1
INTRODUCTION
The ability to detect disease pathogens by the use of peptide microarrays [1–3], which
may be used to detect a variety of biological molecules [4–6], has led to the develop-
ment of immunosignaturing. Immunosignaturing is a technique that has been devised
to create a snapshot or fingerprint of patient pathology at a given point in time [7–14].
This is done by using microarrays preset with randomly generated peptides as a mea-
surement device for patient samples with various antibodies. Antibodies will prefer-
entially bind to peptide sequences based on the sequence order and three-dimensional
shape via molecular associations specified by traditional organic chemistry interac-
tions [15]. For peptides of sufficient length, multiple antibodies are able to bind to
a particular peptide chain, as there are up to seven different epitope regions present
[7]. As greater number of peptide chains, and hence a greater number of microar-
ray spots, are included, the higher the resolution into a variety of diseases, and the
more difficult data analysis becomes especially between multiple measurements. The
focus of this work is to develop adaptive methodologies for immunosignaturing that
are capable of discovering relationships between patient disease states and to group
patients with similar disease states.
1.1 Motivation
One important aspect of immunosignaturing is the construction and interpre-
tation of the microarray data. Randomly generated peptide sequences, in this case
with a length of 17 amino acids and three additional linker peptides, are plated onto
a glass slide capable of holding thousands of such plated samples [7, 9]. Each plated
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spot contains only one peptide type whose amino acid sequence and location on the
plate are known [10]. When a patient sample is applied, molecules from the sample
will preferentially bind to the plated peptides, producing a signature unique to the
patient at a particulate point in time [11, 12]. An example of the microarray plate,
printer, and slide reader is shown in Figure 1.1. This plate construction differs from
traditional microarray work where pathology-specific, known, non-random sequences
are plated instead of randomly generated [16]. The traditional methodology provides
insight into a specific pathogen or gene rather than detecting a variety of pathological
ailments [9]. While immunosignaturing is considered highly sensitive and inexpensive
[17], some critical parameters of the immunosignaturing array include the number of
amino acids included in the random chain, the number of overall sequences included
in the microarray slide, and the time between pathogen exposure and microarray mea-
surement [18]. As demonstrated in [9], immunosignaturing microarrays are capable
of distinguishing disease presence at a variety of time points after exposure.
As more spots with unique sequences are added, data analysis becomes both
challenging and repetitive. Additionally, there is a desire to increasingly add pa-
tient immunosignatures to account for population based variation [19, 20]. Statistical
tools such as the t-test and analysis of variance (ANOVA) are often used for mi-
croarray analysis [21–23], and have been applied to immunosignaturing as well [24].
It should be noted that any down selection that occurs from these statistical tests
would need to be fully repeated every time a new patient immunosignature microar-
ray data set is received. Once peptides of interest are identified, further analysis or
disease classification can be performed to investigate the binding regions [20, 25]. A
variety of clustering and classification schemes were applied to different microarray
data in order to aid in data analysis [26–29]. These methods were also used for im-
munosignaturing analysis [7, 10, 24], however, they required training data and are
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(c)
Figure 1.1: Peptide microarray processing and resulting data: (a) nanoprinter; (b)
microarray reader; and (c) example slide and spots.
not adaptive. This is complicated further by the fact that each peptide can bind to
multiple antibodies and each antibody can bind multiple peptides [30]. This does not
easily allow for the addition of further microarray data for each patient, or for addi-
tional patients to be analyzed without re-implementing the algorithm. Additionally,
these methods do not address the concern of considering fixed versus random data
effects [31]. Supervised learning methods such as support vector machines (SVMs)
were used for improved performance over unsupervised clustering methods [32]. The
SVMs make use of distance measures in higher dimensional feature spaces for effec-
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tive separation and classification. However, they require adequate training datasets,
which may not always be available (e.g., in the presence of a new biothreat). Some
model development for traditional microarray work was investigated to improve over
SVM techniques [33], though a training set is still required. Furthermore, complicat-
ing effects for peptide arrays (such as multiple binding effects and variation between
arrays) are examined in [34], which uses many of the techniques discussed thus far but
applies them to screen out data not deemed useful. Of further interest is the investi-
gation of underlying features within a factor model, as investigated by [35], and using
principal component analysis (PCA) [9, 10]. However, the PCA method assumes that
information content may be maximized across the same orthogonal bases which may
not always be true. Further improvements to the PCA technique was performed us-
ing exploratory factor analysis [24]. Other latent factor models were investigated in
[35] where gene interdependence was examined but individual known sequences were
targeted. Additionally, factor modeling via beta process feature analysis (BPFA) was
examined by [36] for human virus challenge studies paired with patient symptoms,
but this only focused on determining the total number of factors and contributing
genes in each virus challenge.
The presented classification methods and latent factor models are not adap-
tive to changes. Adaptive in this case can mean several things, such as extensible
to additional incoming microarray data, model parameter adaptability on-the-fly for
newly received data, and updated classification based on model factors. An adaptive
clustering scheme based on the Chinese restaurant process (CRP) was presented in
[37, 38] to cluster gene microarray data for gene relationships. A binary clustering
model was presented in [39] that is based on latent feature analysis, but it assumes
that the features act as latent individual clusters, which may be too restrictive. It is
important that the immunosignaturing data model relies on flexible feature relation-
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ships that may not be immediately obvious or known to the user and may require
user information. This approach is useful when those performing the analysis are
not familiar with immunosignaturing, the patient population, or model fitting and
classification algorithms.
Of further interest is the extensibility of the methods to multiple underlying
states, including disease pathologies, for complex classification in disease diagnosis or
for research cases that desire to show disease relationships between multiple diseases.
It is restrictive to assume patients are afflicted with a single condition at any given
time [40], especially since the presence of multiple diseases can require additional
care considerations [41]. Furthermore, disease relationships may be of interest as
diseases may be related leading to similar treatments [42]. Single disease classifica-
tion for immunosignaturing has been investigated for a variety of diseases including
Alzheimer’s [10], influenza [9, 11], glioblastoma [20], and pancreatic disease (includ-
ing type 2 diabetes, pancreatic cancer, pancreatitis, and pre-stage pancreatic cancer)
[8]. No direct extension to multiple states is considered, and the adaptive methods
in [43, 44] are not directly applicable as they assume single disease states. Addition-
ally, these adaptive methods do not provide diagnosis information after classification,
though it would be easy to extend these to classification by the incorporation of a few
known immunosignatures for each known disease. Some similar adaptive methods for
multi-state membership have been discussed in [45], but this method uses the Indian
buffet process ”IBP” to model each different category and relates each separate fea-
ture to each view. Building on the immunosignaturing results discussed in [43, 44],
this would necessitate multiple BPFA runs to generate all the different categories,
which is computationally intensive and redundant. Another method is discussed in
[46], using the IBP to create multiple cluster membership relationships. However,
this approach returns to the assumption that a single feature is indicative of a single
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state and that the clustering feature space is not the same as the latent feature space,
which previous work has shown may not be the best approach for immunosignaturing.
Improved classification was achieved using latent feature spaces for immunosignatur-
ing [44]. As such, there is a desire for an adaptive method that provides diagnosis or
disease relationship information that is capable of multi-disease analysis.
1.2 Thesis Contributions
There are two major contributions in this thesis work that propose unsu-
pervised or semi-supervised adaptive learning clustering algorithms for immune re-
sponses. The first contribution concentrates on patients with immunosignatures re-
sulting from a single state. The second contribution is on patients with multiple
underlying states. Note that we published some of this work in [43, 44, 47, 48].
1.2.1 Single State Clustering
The first part of this work focuses on obtaining immunosignature feature mod-
els for immunosignaturing data analysis. These models mathematically represent re-
lationships between patients and various single underlying states (i.e. diseases) with
limited a priori patient or disease information. Using these features, we propose
methods for adaptive clustering that allow for new incoming patient data, without
requiring us to re-process previous patient or supplemental training data. The main
contributions for the first part of this work are as follows:
• We propose two different approaches for feature extraction that improve immune
state separation. The first approach obtains discriminatory immunosignature
features by modeling the distribution of normalized binding intensities using the
beta probability density function. This allows for multiple distribution shapes
whose parameters can be optimally estimated to succinctly encode information
6
about the distribution of the peptide binding intensities. This is useful when
states may have similar antibody occurrences but in different quantities. The
second approach is an extension of PCA to identify features that encode highly
variable data. The extension to a higher truncation value than previous meth-
ods accounts for greater than 90% of the immunosignature data, and it is useful
when different significant antibodies are present but with similar overall anti-
body distributions. These two methods are used to determine visible spaces as
well as for overall dimensionality reduction techniques.
• We develop an algorithm to extract hidden features from the visible features.
Combining both the visible and latent features, we propose two clustering algo-
rithms: a heuristic algorithm based on the output from the beta process factor
analysis (BPFA) algorithm, and an adaptive Dirichlet process Gaussian mix-
ture modeling (DP-GMM) algorithm. Both clustering methods are based on
the novel interpretation of a modified BPFA binary feature matrix to allow for
combinations of features to describe single states. This modification allows for
the novel introduction of reward or penalty criteria for various clustering condi-
tions that are application specific. The user can then account for a wide range
of cases, including cases with a low tolerance for error and cases that are more
tolerant to allow for feature relationship discovery.
• We develop methodologies for unsupervised identification of disease features
linked directly to unique patient groups, using only the patient immunosignature
median intensity values and requiring no training data or additional information.
This is a novel application in the immunosignaturing space.
These main contributions are based on several proposed methods. The PRE-
DICT (PCA REsolution with DPGMM for Immunosignature Classification Testing)
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B-PREDICT (Beta PDF REsolution with DPGMM for Immunosignature Classifica-
tion Testing) methods use DP-GMMs to identify groupings given PCA and beta dis-
tribution parameters, respectively [43, 47]. These methods assume that each patient
belongs to only one group. By using the blocked Gibbs Markov chain Monte Carlo
(MCMC) algorithm, Gaussian distributions are constructed for each group. This can
lead to misclassification and disease state misdiagnosis. The DP-GMM based meth-
ods allow adaptive identification of groupings between immunosignatures using only
the microarray median intensity data and further allows clustering of novel groupings
without the need for a training data set. While these methods show promising results,
for some cases the features are not always clearly associated with a single group.
In the Z-PREDICT (Z matrix from PCA REsolution and Discovery for Im-
munosignature Classification Testing), Φ-PREDICT (Φ PCA REsolution and Discov-
ery for Immunosignature Classification Testing) and ZB-PREDICT (Z matrix from
Beta PDF REsolution and Discovery for Immunosignature Classification Testing),
beta process factor analysis (BPFA) is used to identify latent features within the
data set and with the possibility of multiple feature grouping for each disease state
[44]. Note that this happens after the visible features are identified and encoded in
the data. In fact, this method produces a ”feature fingerprint” for each of the states
which can then be used for clustering and ultimately disease identification. The BPFA
is also able to highlight the relationship between the peptide sequences and latent fea-
ture groups, though further investigation of this phenomena is outside the scope of
this work. This provides a method for identifying spots which may be related to par-
ticular diseases without re-running the microarray for each disease state separately.
Again, by using a blocked Gibbs sampler, the posterior distribution parameters that
mathematically describe these relationships can be estimated. These methods are
further extended to include DP-GMM clustering in BIO-PREDICT (BPFA Including
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prOcessing with PCA REsolution and DP-GMM for Immunosignature Classification
Testing) and BIOB-PREDICT (BPFA Including prOcessing with Beta PDF REs-
olution with DP-GMM for Immunosignature Classification Testing), leading to an
adaptive clustering method that is paired with the adaptive model determination of
the latent features.
The ability to adaptively determine underlying features for immunosignatures
with the possibility of recognizing novel features over time is new to immunosigna-
turing. In both the DP-GMM and BPFA, new patient data may be considered as it
is received without changing the clustering of previously analyzed patients. While we
achieved good performance, BPFA clustering alone becomes difficult for immunosig-
naturing due to the multiple feature combinations and multiple patients. As such,
adaptive clustering is shown to perform better when DP-GMM is combined with
BPFA.
1.2.2 Multiple State Clustering
The contributions for the first part of this work focuses on single underlying
states in patients, which may be too restrictive in practice. As a patient may have
multiple disease states, each data entry needs to be classified into multiple groups.
In addition to multiple diseases per patient, it is also possible that a single disease
has multiple stages or state relationships need to be explored, such as phylogenic tree
creation for multiple disease states. As such, additional contributions are provided
for multiple underlying states. Although these contributions are used for clustering
immunosignaturing data with multiple underlying diseases, our approach of combin-
ing adaptive methodologies is novel and our proposed methods are flexible enough for
adaptation to a variety of problems, even outside of the medical immunosignaturing
area. The main contributions for this work are as follows:
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• We propose a novel method for multi-state analysis and clustering that builds
upon the corresponding single state methods, and we develop unique comparison
criteria. The multi-state analysis is based upon the presumption that feature
combinations are indicative of single disease states, but we also allow integration
of the feature that combinations to indicate multiple states. Furthermore, the
new combination of visible feature spaces and latent feature spaces allows us
to capture cases of initial data with high variability and data with different
distributions.
• We develop a flexible method based on the hierarchical Dirichlet process (HDP)
that combines the visible features (from PCA or beta distribution fitting) and
latent features (from BPFA) and then compares the overall features using a
modified binary feature matrix comparison to enable adaptive clustering across
multiple data groups. Direct application of the HDP to the multi-state features
without the modified feature matrix does not yield good performance unless
additional data processing steps are performed to extract the clustering results.
This novel, enabling step also allows for the introduction of penalty or reward
conditions for various comparisons that are application specific. This allows
for flexibility across a variety of conditions where either strict user conditions
create low tolerance for error, or where some variation is allowed for the sake of
discovery. Additionally, this approach allows the novel determination of present
states without the need for state significance thresholding specified by the user
as well as reduced subjective user interaction.
• We develop the multi-state analysis for immunosignaturing data and key dis-
ease state data with flexible parameters to allow subsequent refinement and
expansion of the algorithms linked to possible biological phenomena for better
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understanding. This intentional design allows the algorithms to be refined in a
meaningful way as additional biological information is generated.
These main contributions are based on several proposed methods. The first
method is an extension of the Z-PREDICT and ZB-PREDICT methods to allow
for the comparison of n > 1 state possibilities. These methods are referred to as
Z-PREDICTn (Z-matrix from Beta PDF REsolution and Discovery for Immunosig-
nature Classification Testing up to n-states) and ZB-PREDICTn (Z-matrix from Beta
PDF REolution and Discovery for Immunosignature Classification Testing up to n-
states). While not adaptive, these methods allow for classification assuming that a
number of underlying states is known [47]. In this method, the BPFA is provided
with key state data and dataset information, and an average profile for each single
state is constructed. The unknown state data is then compared to this average key
data to achieve a ranking profile for each data entry and each state.
In order to eliminate the need to know underlying state information, we de-
velop the H-PREDICT (HDP of PCA REsolution and Discovery for Immunosignature
Classification Testing) and HB-PREDICT (HDP of Beta PDF REsolution and Dis-
covery for Immunosignature Classification Testing) methods. In these cases, the state
ranking profiles for each unknown data entry is classified using the HDP, allowing for
common clustering criteria over each distinct ranking profile. It should be noted that
without the ranking comparison described in Z-PREDICTn and ZB-PREDICTn, the
direct application of the HDP or even the DP-GMM is not possible. This is because
each immunosignature entry would still only be assigned to a single cluster.
1.3 Immunosignaturing Descriptions
A variety of datasets are used throughout this work to demonstrate the various
algorithms. In order to show functionality for single state algorithms, a state is
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defined as a single disease and each data entry is the corresponding information, i.e.
immunosignature, for each patient. In the case of multi-state algorithms, a state is still
considered an underlying disease, but each patient (i.e. data entry) is assumed to have
more than one underlying disease. Additionally, different methods require different
definitions of classification success. Immunosignaturing data from the Arizona State
University Biodesign Institute [14] was used to demonstrate the performance of each
method. Median peptide intensity was used for all analysis. It should be noted that
the disease selection is irrelevant for these data set constructions. Any combination
of diseases could have been selected. As such, any deviations from these datasets is
discussed in the corresponding results sections. Additionally, while there are roughly
10,000 unique sequences present in the array, they are often replicated at least once.
As such, where applicable, datasets are reduced first by averaging together the median
intensity values of repeated sequences.
1.3.1 Single Disease Dataset Descriptions
Microarray data sets for each patient derived from the CIM10K microarray
template [9] were used. All methods described in this section were performed on
several distinct datasets. Dataset 1 consists of 30 individuals with one of six disease
states: breast cancer, normal, glioma, cocci, sarcoma, and asthma post. The patient
order is according to the disease order just listed. No species or time point infor-
mation is specified for these individuals. These are sometimes identified as C1-C6
respectively on corresponding Dataset 1 tables. Dataset 2 consists of 25 individuals
with one of five disease states: Alzheimer’s, asthma, influenza, Q-fever, and normal.
These are sometimes identified as C1-C5 respectively on the corresponding Dataset
2 tables. Again, patients are placed in the dataset per the disease order previously
indicated. No time point information is specified for these individuals. Individuals
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in the Alzheimer’s, influenza and normal are from human samples, Q-fever individ-
uals are mouse sample, and asthma samples are unspecified. No species information
is used in the analysis and all immunosignatures are analyzed in the same manner.
Median intensity values from the immunosignaturing microarrays are used, and all
control sequences and machine mis-reads are removed from the datasets before anal-
ysis. Data types were chosen to represent a variety of disease states and even species
where applicable, in order to show that no prior information is required other than
the median intensity data to separate patient populations.
1.4 Report Organization
The dissertation is organized as follows. Chapter 2 provides background on the
DP-GMM and the blocked Gibbs sampler, develops the PREDICT and B-PREDICT
clustering algorithms and provides simulations of the algorithm performance. Chapter
3 presents theBPFA using the blocked Gibbs sampler and presents the Z-PREDICT
and ZB-PREDICT algorithms with corresponding clustering results. The DP-GMM
and BPFA are combined to form the BIO-PREDICT and BIOB-PREDICT clustering
algorithms which are discussed in Chapter 4 with corresponding immunosignature
clustering results. Chapter 5 proposes and demonstrates the performance of multi-
state clustering algorithms Z-PREDICTn and ZB-PREDICTn. The HDP is discussed
in Chapter 6 and the H-PREDICT and HB-PREDICT clustering algorithms and
their performances are presented. The performance of different proposed clustering
algorithms is compared with the performance of a naive Bayes classifier in Chapter
7. Finally, in Chapter 8, conclusions and extensions to future work are discussed.
A graphical depiction of the clustering algorithm progressions is given in Figure 1.2.
The direction of the arrows demonstrates the flow of each algorithm, and the steps
needed by the algorithm are given by the boxes the arrow line crosses. For example,
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BIO-PREDICT is obtained using PCA features, BPFA features, BPFA feature matrix
analysis, and DP-GMM. The acronyms used in the dissertation are summarized in
Table 1.1, and the acronyms we used for the proposed clustering algorithm names are
defined in Table 1.2.
Figure 1.2: Summary depicting proposed clustering algorithms.
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Table 1.1: Alphabetical list of acronyms used in this dissertation.
Acronym Description
BP Beta Process
BPF Beta Probability Distribution Function Fit
BPFA Beta Process Factor Analysis
CMA Circular Moving Average
CRP Chinese Restaurant Process
CRF Chinese Restaurant Franchise
DP Dirichlet Process
DP-GMM Dirichlet Process Gaussian Mixture Model
GMM Gaussian Mixture Model
HDP Hierarchical Dirichlet Process
IBP Indian Buffet Process
LOF Left Ordered Form
LOOCV Leave One Out Cross Validation
MCMC Markov Chain Monte Carlo
MDD Multi-Disease Dataset
MLE Maximum Likelihood Estimator
PCA Principle Component Analysis
PDF Probability Distribution Function
RIC Relaxed Immunosignaturing Clustering/Classification
SIC Strict Immunosignaturing Clustering/Classification
SSLB Single State Lower Bound
SSUB Single State Upper Bound
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Table 1.2: Alphabetical list of acronyms for proposed clustering algorithms.
Acronym Description
BIO-PREDICT BPFA Including prOcessing with PCA REsolution and
DP-GMM for Immunosignature Classification Testing
BIOB-PREDICT BPFA Including prOcessing with BetaPDF REsolution with
DP-GMM for Immunosignature Classification Testing
B-PREDICT BetaPDF REsolution with DP-GMM for Immunosignature
Classification Testing
HB-PREDICT HDP of Beta PDF REsolution and Discovery for
Immunosignature Classification Testing
H-PREDICT HDP of PCA REsolution and Discovery for
Immunosignature Classification Testing
PREDICT PCA REsolution with DP-GMM for Immunosignature
Classification Testing
ZB-PREDICT Z-matrix from Beta PDF REsolution and Discovery for
Immunosignature Classification Testing
ZB-PREDICTn Z-matrix from Beta PDF REsolution and Discovery for
Immunosignature Classification Testing up to n-states
Z-PREDICT Z-matrix from PCA REsolution and Discovery for
Immunosignature Classification Testing
Z-PREDICTn Z-matrix from PCA REsolution and Discovery for
Immunosignature Classification Testing up to n-states
Φ-PREDICT Φ PCA REsolution and Discovery for Immunosignature
Classification Testing
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Chapter 2
FEATURE SELECTION AND ADAPTIVE CLUSTERING USING DIRICHLET
PROCESS GAUSSIAN MIXTURE MODELING
Processing immunosignature data can be computationally intensive due to the large
number of spots on a single array and the fact that there is at least one microarray
sample for each patient of interest. Immunosignature microarrays are designed to
have a large number of random peptide sequences; the CIM10K array has 10,000 se-
quences [9] and the most current immunosignature microarray technology has 330,000
sequences [14]. As a result, we want to reduce processing complexity without unnec-
essarily losing the relationship between patients and disease state. It is also important
to develop a processing method that does not require significant patient, disease state,
immunosignaturing, or microarray knowledge for accurate performance. We consider
two feature models for data reduction and discernible feature space mapping: princi-
pal component analysis (PCA) and beta probability density function fitting (BPF).
Once features that depend on disease states are extracted, clustering can be performed
to group patients according to disease state. We specifically consider the Dirichlet
process Gaussian mixture model approach to design an adaptive, unsupervised clus-
tering method without requiring prior training data.
2.1 Principal Component Analysis
The PCA method was previously used for immunosignature feature extraction
to reduce the overall data dimensionality of the median peptide intensities [9, 10].
PCA is a general technique that seeks to approximate a signal by removing redun-
dancy, retaining only essential signal properties [49, 50]. The immunosignaturing
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data has high dimensionality (∼ 104) and the number of patient samples (∼ 5 to 100)
is much smaller than the dimensionality. Due to the large difference between data
dimensionality and samples, a modified covariance estimate is required to achieve a
robust PCA representation [51]. Without this approximation, PCA would result in
high condition numbers and large estimation errors.
Given a vector x = [x1 x2 . . . xN ] of N data points the PCA representation
is given by [52, 53]:
x = µx + ΛΓ +  (2.1)
where Γ is a matrix of factor parameters, Λ is a vector of the eigenvalues λ1, λ2, . . .,
µx is a vector of data means, and  is the error vector. PCA generally requires that
the mean vector is removed before the decomposition. The model assumes that [52]:
E[x] = E[] = E[Γ] = 0. (2.2)
E[·] denotes the expectation operator. The covariance matrix Cx of the zero-mean
data is given by:
Cx = ΛΛ
T + C∆ (2.3)
where C∆ = E[
T ] is the error covariance matrix. For very large N , a large covari-
ance matrix needs to be reliably calculated. The sampled version does not provide a
good estimate of the covariance matrix of x due to the large data dimensionality. In-
stead, we use an improved covariance estimate using sample shrinkage. The estimate
of the i, jth element of the covariance matrix, i, j = 1 . . . N is given by [51]:
Cˆi,j =

σi,i i = j
rˆi,j
√
σi,iσi,j i 6= j
(2.4)
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where rˆi,j is the correlation estimate and ρ is the estimated shrinkage intensity [51]:
rˆi,j =

1 i = j
ri,j min(1,max(0, 1− ρ)) i 6= j
(2.5a)
ρ =
∑
i 6=j σ
2
ri,j∑
i 6=j r
2
i,j
(2.5b)
σri,j is the estimated variance of sample correlation ri,j, si,j is the sample variance:
si,j =
1
κ− 1
κ∑
k=1
(xk,i)− x¯j (2.6a)
x¯i =
1
κ
κ∑
k=1
xk,i (2.6b)
where x¯i is the sample mean and xk,i is the kth observation of xi, k = 1, . . . , κ. If
we normalize xi to have zero mean and unit variance, we can obtain the estimate
variance of the correlation in equation (2.5b) as [54]:
σ2ri,j =
κ
(κ− 1)3
κ∑
k=1
(w∗k,j,i − w∗i,j)2 (2.7)
where:
ri,j =
κ
κ− 1w
∗
i,j, (2.8a)
w∗i,j =
1
κ
n∑
k=1
w∗k,i,j, (2.8b)
w∗k,i,j = (x
∗
k,i − x∗i )(x∗k,j − x∗j) (2.8c)
x∗i =
1
κ
n∑
k=1
x∗k,i (2.8d)
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When applying this modified covariance estimate, it is possible to produce a
more robust PCA representation that contains more accurate eigenvalues [51]. Once
the data dimensionality is reduced, the log of the PCA components is taken in order
to address the scale discrepancy between dimensions. The reduced data dimension-
ality is found by performing eigenvalue analysis and keeping only components with
sufficiently large eigenvalues. It is up to the researcher to determine what percentage
of the original data is kept. This percentage can be calculated by dividing the sum
of the kept eigenvalues over the total of all eigenvalues. For the immunosignature
data, the number of unique peptide microarray spots per patient and the reduced di-
mensionality is the median intensity of the microarray spots mapped to the log PCA
domain (i.e. log of the linear combination of the median intensity of the microarray
spots). Note that the log was used to help with feature space separation.
2.2 Beta Probability Density Function Fitting
The second method for feature extraction is based on fitting microarray bind-
ing intensity data to the parameters of beta probability density functions (PDFs)
[57–61]. The beta PDF fitting (BPF) approach uses maximum likelihood to estimate
the beta PDF parameters that best fit a microarray data sample [55, 56]. These
beta distribution parameters are used to define the dimensionality and encode the
immunosignaturing behavior in a limited number of parameters. This is also a repre-
sentation of the visible process features (median intensity distributions) that the user
can discern by data examination. The two beta distribution parameters α and β cre-
ate the two-dimensional space, effectively reducing the dimensionality from ∼10,000
to 2. While this is a dramatic dimension reduction, it provides a good first estimate of
the intensity behaviors between the different populations without running individual
statistics between all of the groups and without individually investigating every pep-
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Figure 2.1: Example of beta probability density functions.
tide comparison between groups. Two example histograms are given in Figure 2.2,
one for a patient with breast cancer and one with normal pathology, with beta PDFs
fitted for each patient using un-normalized median intensity immunosignature data.
Note that in the algorithm the data is normalized for patients so that the intensity
values are between 0 and 1. This is required in order to use the beta PDF, which is
only defined between 0 and 1. The beta PDF is selected because of the diverse PDF
shapes that may be described by its α and β parameters, as seen in Figure 2.1. The
beta PDF for the nth patient, n = 1, . . . , N is given by [62]:
β(xl,n;α, β) =
Γ(α + β)
(Γ(α)Γ(β))
xl,n
α−1(1− xl,n)β−1 (2.9)
where xl,n, l = 1, . . . , D is the lth microarray data value for the the nth patient.
The beta PDF parameters that best fit the data of the n patient are found using
maximum likelihood estimation (MLE) as:
{aˆn, bˆn} = arg max
α,β
D∏
l=1
β(xl,n;α, β) , (2.10)
21
0 0.005 0.01 0.015 0.02 0.025 0.03
0
500
1000
1500
2000
2500
3000
Bins
N
um
be
r o
f I
nt
en
sit
y 
Va
lu
es
 p
er
 B
in
(a) Histogram of the intensity values for a
patient with breast cancer and the beta
PDF that best fits the data.
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(b) Histogram of the intensity values for a nor-
mal patient with and the beta PDF that best
fits the data.
Figure 2.2: Beta PDFs fit to histograms of patient immunosignaturing data.
where α and β are the PDF parameters. This can be extended to the N patients
within the data set such that there are now vectors of parameters that fully describe
the set of immunosignaturing datasets for various patients, where each dataset has a
single αˆn and αˆn value found using MLE. Modeling the distribution of D-dimensional
normalized binding intensities xn = [x1,n, x2,n, . . . , xD,n] for the nth patient, n =
1, . . . , N , we can obtain the PDF parameter vectors:
α = [αˆ1, αˆ2 . . . , αˆN ], (2.11a)
β = [βˆ1, βˆ2 . . . , βˆN ] (2.11b)
The resulting output is that the nth patient is characterized by the two beta PDF
parameters αˆn and βˆn describing the beta PDF created by its median intensities.
2.3 DP-GMM Clustering of Immunosignatures
In order to facilitate adaptive clustering of immunosignature data, we model
data features using Dirichlet process Gaussian mixture models. Modeling features
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reduces the large dimensionality of the immunosignatures and thus the computational
cost of the clustering algorithm; it also provides insight into the relationships between
patients with similar diseases.
2.3.1 Conjugate Priors
Before discussing the DP-GMM clustering algorithm, we first provide some
background on conjugate priors from a Bayesian setting, on Dirichlet processes and
on Gaussian mixture models. If the posterior distributions p(θ|x) are in the same
family as the prior probability distribution p(theta), the prior and posterior are then
called conjugate distributions, and the prior is called a conjugate prior for the like-
lihood function. Markov chain Monte Carlo MCMC methods and blocked Gibbs
sampling algorithms are built upon the premise of conjugate priors. This views pa-
rameter estimation as a Bayesian inference problem where the posterior PDFs are
estimated based on data used for estimation [63]. This exploits a conjugate prior re-
lationship that explicitly describes these parameter relationships in a Bayesian sense.
Considering a random data vector x and a random parameter vector ψ, and assum-
ing similar statistical characteristics for the posterior PDF p(ψ|x) and the prior PDF
p(ψ), then the posterior and prior PDFs are considered conjugate distributions. The
prior PDF is then the conjugate prior for the likelihood function p(x|ψ) [63–65]. The
relationship between these PDFs is given by Bayes theorem as:
p(ψ|x) = p(x|ψ)p(ψ)
p(x)
(2.12)
This relationship is often represented as:
p(ψ|x) ∝ p(x|ψ)p(ψ) (2.13)
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The term hyperparameter is also used in the context of conjugate priors. Hy-
perparameters are PDF parameters that have their own prior distributions and can
be estimated using MCMC methods [3]. Essentially, it is a distribution over the
parameters of a particular distribution. Initial distributions with conjugate priors
are chosen for their known relationships and ease of implementation to create more
efficient algorithms.
2.3.2 Dirichlet Process and Gaussian Mixture Modeling
Using conjugate priors, we discuss next Gaussian mixture modeling (GMM)
and the Dirichlet process (DP). The DP-GMM is used in a variety of applications [66–
69] to model data distributions using an unlimited number of mixture components
[70]. Given a data or feature vector x, a mixture model is described by the PDF
p (x|θ1, . . . ,θM) =
M∑
m=1
wm p (x;θm) , (2.14)
where {w1, . . . , wM} are the individual mixture component weights, θm is the parame-
ter space representing the PDF p(x|θm), and M is the number of mixture components
[71]. The goal of the mixture model is to estimate M , wm, and θm, m = 1, . . . ,M that
best fit this data. The DP-GMM provides an adaptive approach to determine cluster
model parameters [72] where an infinite number of mixture components and weight-
ing factors are theoretically possible [73]. In this case, p(x;θm) ∼ N (x;µm,Σm) is a
Gaussian PDF with a parameter vector consisting of the mean and covariance of the
PDF, θm = {µm,Σm}. Therefore, the mixture model can be specified with Gaussian
distributions such that a complete representation of clustering in the space is:
p (x|w,µ,Σ) =
M∑
m=1
wmN (x;µm,Σm) . (2.15)
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In a Bayesian sense, a prior PDF must be selected in order to determine the
nonparametric statistics related to a dataset. The DP is a prior in which a base
distribution, G0, and an innovation parameter α, fully describe the DP [71]. The
innovation parameter effectively describes how likely a new data point is to be placed
within a cluster of previous data or in a newly formed cluster. In the stick-breaking
algorithm of the DP [74], this corresponds to how fine the breaks or cluster divisions
are made. Consider the distribution [75]:
G ∼ DP(α,G0), (2.16a)
θn|G ∼ G, n = 1, . . . , N. (2.16b)
that is drawn from a DP with innovation parameter α and base distribution G0
with {θ1, . . . ,θN}. Then, G0 is the expected value of G and α determines how
close G is to G0. In particular, G is discrete and has the following stick-breaking
representation [74]:
θm ∼ G0, m = 1, . . . ,∞
vi ∼ Beta(1, α), i = 1, . . . ,∞
wm = vm
m−1∏
i=1
(1− vi), m = 1, . . . ,∞
G(θ) =
∞∑
m=1
wm δ(θ − θm) . (2.17)
where where δ(·) is the Kronecker delta function. This designation comes from the
idea that a unit length stick may be broken such that the size of each successive
break is representative of wm = Pr (θ = θm). To understand the assignment to a
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particular cluster θn, it is possible to integrate out G, thus describing the Po´lya urn
relation [70, 76–79] given by:
p(θn|Θ(−n), α,G0) = 1
α +N − 1
N∑
n′=1
n′ 6=n
δ(θn − θm) + α
α +N − 1 G0(θn), (2.18)
where Θ(−n) are the parameters except for θn, and N
(−n)
m is the number of variables
in Θ(−n) that are equal to θm. This representation may be rewritten as:
p(θn|Θ(−n), α,G0) = 1
α +N − 1
M∑
m=1
N (−n)m δ(θn − θm) +
α
α +N − 1 G0(θn) (2.19)
This further helps to illustrate the functionality of the innovation parameter, α. In
particular, the probability of choosing an existing cluster value is given as Pr(θm =
θn) = N
(−n)
m /(α + N − 1), and the probability of selecting a new cluster value is
given by Pr(θm 6= θn) = α/(α + N − 1). This then leads to the DP-GMM repre-
sentation as described in Equation (2.15) whose corresponding stick-breaking process
representation is given as:
θm ∼ G0, m = 1, . . . ,∞, (2.20a)
vk ∼ Beta(1, α), k = 1, . . . ,∞, (2.20b)
wm = vm
m−1∏
k=1
(1− vk), m = 1, . . . ,∞, (2.20c)
cn|w ∼ Categorical(w), n = 1, . . . , N, (2.20d)
xn|cn ∼ p(xn|θcn), n = 1, . . . , N. (2.20e)
The variable cn indicates which of the M possible clusters includes xn and categor-
ical refers to the assignment to one of the M possible clusters. While in theory the
DPGMM is infinite, a practical truncation limit may be selected such that the trun-
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cated representation is a close approximation of the infinite case, and it can also help
to simplify the numerical calculations for approximating the DP [80]. This limit M ,
can be set by the user or it can be calculated directly. The truncation error is related
to M and is given by [81]:
4N exp(−(M − 1)/α). (2.21)
In actuality, the value of M may be larger than the true number of latent clusters for
a particular data set. Additionally, if M is calculated, then it can be adjusted by the
innovation parameter α, as in Equation (2.21).
2.3.3 The Dirichlet Process and Blocked Gibbs Sampler
This conjugate prior relationship is used extensively to simplify calculations for
posterior distributions estimated using the blocked Gibbs sampler algorithm. Using
an MCMC technique such as the blocked Gibbs sampler, it is possible to iteratively
estimate posterior distribution parameters [82]. Considering the mixture model given
in Equation (2.14) and using the notation of Equation (2.20), the blocked Gibbs
sampler, at the ith iteration in the Markov chain estimates [80, 82]:
θ(i)m ∼ p (θm|c(i−1),xn), m = 1, . . . ,M, (2.22a)
c(i)n ∼ p (cn|Θ(i),w(i−1),xn), n = 1, . . . , N, (2.22b)
w(i)m ∼ p (wm|c(i)), m = 1, . . . ,M. (2.22c)
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These can be expressed in terms of conjugate prior relationships [80]:
p (θm|c,xn) ∝ G0(θm)
∏
n:cn=m
p (xn|θ), m = 1, . . . ,M, (2.23)
p (cn|Θ,w,xn) =
M∑
m=1
(
wm p (xn|θm)
)
δ(cn −m), n = 1, . . . , N, (2.24)
p (wm|c) = vm
m−1∏
j=1
(1− vj), m = 1, . . . ,M (2.25)
where vm is also defined as:
vm ∼ Beta
(
1 +N∗m, α +
M∑
m′=m+1
N∗m′
)
, (2.26)
and n : cn = m denotes the indices in c such that cn = m, and N
∗
m is the number of
elements in c that are equal to m.
While this describes the conjugate prior relationship, the specific mathematical
equations for the BGS execution require the selection of the prior and likelihood
distributions. In the case of the DP-GMM, the likelihood distribution is Gaussian
where as the prior distribution, G0 is Normal-Wishart. The Normal-Wishart PDF is
used because this is the multidimensional generalization for the DPGMM. Thus, the
relationship between the prior and posterior distributions may be described by [63]:
G0(θ) , NW (µ,Σ−1 ; µN , τN , ξW , ιW) , (2.27a)
p (θ|c,X) , NW (µ,Σ−1 ; µ˜N , τ˜N , ξ˜W , ι˜W) (2.27b)
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The hyperparameters µN , τN , ξW , ιW , µ˜N , τ˜N , ξ˜W , ι˜W are described by [63]:
µ˜N =
τN µN +Nµx
τN +N
, (2.28)
τ˜N = τN +N , (2.29)
ι˜W = ιW + Σx + τN N
τN +N
(µN − µx) (µN − µx)T , (2.30)
ξ˜W = ξW +N , (2.31)
and µx and Σx are the mean and covariance of X, and µN , τN , ξW , and ιW are user
specified with the restrictions:
τN > 0, (2.32a)
ξW > D − 1 (2.32b)
where D is the number of dimensions in x. The algorithm and further description
of the update equations for the implementation of the blocked Gibbs sampler are
provided in Algorithm 1.
Gaussian mixture modeling in the Bayesian sense is described as using a Gaus-
sian prior to probabilistically describe data subgroup behavior within an overall data
population. The mixture of subgroup distributions defines group membership with-
out providing group identification. The DP is one such method of yielding subgroup
clusters, and it may rely on various distributions to describe the data behavior by
way of features [73]. In the immunosignaturing case, the distributions correspond to
the normalized binding intensities, which may have a variety of distribution shapes.
The learning of the associated distribution parameters can be done via recursive es-
timation through construction of a Markov chain.
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2.4 DP-GMM Immunosignature Clustering Algorithms
2.4.1 DP-GMM Clustering with PCA Features
While the DPGMM is an effective way to adaptively cluster various data sets,
it can be computationally intensive. Thus, the PREDICT, or PCA REsolution with
DPGMM for Immunosignature Classification Testing is presented to help analyze im-
munosignaturing data. PREDICT uses the log results of principal component analysis
(PCA) for dimensionality reduction followed by the DPGMM for classification. In
this way, patients are clustered with other patients sharing similar feature character-
istics, in this case PCA features. One underlying assumption for this method is that
the patient will have only a single disease pathology. This is due to the fact that
the DPGMM will assign each patient to a single cluster during each iteration of the
blocked Gibbs sampler. While average values are computed based on a user specified
number of sample iterations, the end result is still a single cluster assignment.
2.4.2 DP-GMM Clustering with Beta PDF Fitting Features
There are alternative feature reduction schemes to PCA, including beta PDF
fitting, as discussed here. The B-PREDICT, or Beta PDF REsolution with DPGMM
for Immunosignature Classification Testing, algorithm uses Beta PDF fitting to re-
duce the immunosignaturing feature space, and then feeds a scaled result of that
into the DPGMM. The scaling is left to the user, and is simply available to avoid a
small numbers problem when clustering. In this manner, B-PREDICT is identical
to PREDICT, except that it uses Beta PDF fitting to reduce the feature space, and
as such requires less computations than the PCA based method (e.g. for a modified
covariance matrix), and the feature space will always be two dimensions.
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2.5 DP-GMM Clustering Results
2.5.1 Strict and Relaxed Immunosignaturing Clustering Criteria
Before discussing the results for each of the methods, it is helpful to define
what is considered correct or successful classification. When dealing with biological
disease data amongst patients, it is possible that different patients, although having
the same disease, will have different responses to diseases. Physically this may cor-
respond to a range of symptoms, their severity, their progression over time, etc. For
example those infected with influenza may experience a combination of a variety of
symptoms [83]. While each patient may have a slightly different disease expression
for a particular disease state, in general it is possible to group individuals by these
expressions. However, this may result in multiple groupings that describe the same
disease state. As such, we discuss a strict and a relaxed definition of immunosigna-
turing clustering success.
In the strict immunosignaturing clustering/classification definition (SIC), only
one group may exist per disease state and any individual falling outside the group
whose ground truth would indicate the same disease will be seen as a misclassification.
In the relaxed immunosignaturing clustering/classification (RIC) definition, multiple
groups may be used to represent a single disease as long as two or more individuals
are present in this additional group. However, it will be considered a misclassification
if individuals from another disease state are incorrectly placed in this group. It is
believed that these two definitions will offer some flexibility to compare the results
from the various methods, but without allowing various algorithm parameters to
be set such that each patient is considered a new group. In some cases it may be
more appropriate to use the SIC definition of classification success if no underlying
relationship indicating multiple groupings is available. For example, a training set of
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data may be used to help determine if multiple groups are present for a particular
disease state. In cases where an underlying relationship is present, it may be more
appropriate to use the RIC definition of classification success.
2.5.2 Results Using the PREDICT Clustering Algorithm
In order to demonstrate the clustering performance of the DP-GMM based
algorithms, we use the datasets described in Chapter 1. As previously stated, the
dimensionality in this case is defined by the PCA of the microarray median intensity
data assuming that the dimensionality is defined by the number of peptide sequences.
After PCA, dimensionality is defined as linear combinations of peptide intensity re-
sults determined by the significant eigenvalues from the PCA. The PCA algorithm
was applied as in equations (2.1) and (2.4) and the log was taken as the input to the
DPGMM. At minimum, the first three principle components were selected for Dataset
1, which represents 93.5% of the data, and the first five principal components were
used from Dataset 2 which represents 93.5% of the data. Further dimensions may be
added if desired from the PCA results, but the number of components was selected
based on the plots of the eigenvalues as shown in Figure 2.3.
The confusion matrices for Dataset 1 with diseases identified as C1-C6 may
be found in Table 2.1 and 2.2. The innovation parameter α was set to 15, the error
was set to 5x10−1, which produced a truncation of M = 83. For the blocked Gibbs
sampler, 2000 iterations were done for burn-in and 2000 sample iterations were then
performed. The dataset 1 PREDICT results of the clustering can be seen in Figure
2.4. The true disease states are color coded for viewing ease, and the bar heights
indicate class assignments by the algorithm. Another representation is given in the
same figure to help show how bar heigh relates to the clustering results where each
face represents a patient, and the color is indicative of the ground truth disease
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(a) Eigenvalue plot from Dataset 1.
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(b) Eigenvalue plot from Dataset 2.
Figure 2.3: The first 20 significant eigenvalues from PCA analysis of each dataset.
information. In this depiction, patient color represents the underlying disease and
cluster color represents the corresponding cluster for each disease. Instances with
matching patient and cluster colors are correct clustering and instances with different
colors are incorrect clustering. The correct classification for both SIC and RIC was
60%. The confusion matrices for Dataset 2 with diseases identified as C1-C5 may be
found in Table 4.3 and 4.4. The innovation parameter α was set to 35, the error was
to 1x10−4, which results in M = 485. For the BGS, the number of burn-in iterations
was set to 2000 and the number of sample iterations was set to 3000. The dataset 2
PREDICT results can be seen in Figure 2.5; the SIC and RIC results were both 64%.
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(b) Clustering results using PREDICT.
(c) Clustering results using PREDICT.
Figure 2.4: PREDICT results for Dataset 1
Class C1 C2 C3 C4 C5 C6
C1 4/5 0/5 1/5 0/5 0/5 0/5
C2 0/5 0/5 1/5 0/5 4/5 0/5
C3 1/5 0/5 4/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 3/5 0/5
Table 2.1: Dataset 1 PREDICT SIC
confusion matrix.
Class C1 C2 C3 C4 C5 C6
C1 4/5 0/5 1/5 0/5 0/5 0/5
C2 0/5 0/5 1/5 0/5 4/5 0/5
C3 1/5 0/5 4/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 3/5 0/5
Table 2.2: Dataset 1 PREDICT RIC
confusion matrix.
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(c) Classification results using PREDICT
Figure 2.5: PREDICT results for Dataset 2
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Class C1 C2 C3 C4 C5
C1 3/5 0/5 0/5 0/5 0/5
C2 0/5 3/5 0/5 0/5 0/5
C3 0/5 0/5 1/5 0/5 4/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 2.3: Dataset 2 PREDICT SIC
confusion matrix.
Class C1 C2 C3 C4 C5
C1 3/5 0/5 0/5 0/5 0/5
C2 0/5 3/5 0/5 0/5 0/5
C3 0/5 0/5 1/5 0/5 4/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 2.4: Dataset 2 PREDICT
RIC confusion matrix.
2.5.3 Results Using the B-PREDICT Clustering Algorithm
B-PREDICT was used to analyze Dataset 1 and 2 whose MLE fit Beta PDF
feature space may be seen in Figures 2.6 and 2.7. For Dataset 1, α = 15 and the
error was set to 1, which gives a truncation of approximately M = 73, and 2,000
burn-in iterations were done in the blocked Gibbs sampler followed by 2,000 itera-
tions for sampling. The confusion matrices with disease identified as C1-C6 are given
in Tables 2.5 and 2.6. The true disease states are color coded for viewing ease, and
the bar level for each measurement is the class membership per the final clustering.
Using SIC, a rate of 70% was achieved as compared to a classification rate of 76.7%
for RIC. For Dataset 2, the innovation parameter was set to α = 45 and the error
was 0.1, giving M = 312. The number of burn-in iterations was set to 2000 and the
number of sample iterations was set to 3000. The SIC and RIC were each 64%.
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(b) Clustering results.
Figure 2.6: B-PREDICT results for Dataset 1.
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Figure 2.7: B-PREDICT results for Dataset 2.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 2/5 0/5 0/5 0/5 1/5
C3 0/5 0/5 4/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 3/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 1/5 1/5 0/5 0/5 0/5 2/5
Table 2.5: Confusion matrix for
Dataset 1 B-PREDICT using SIC.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 2/5 0/5 0/5 0/5 1/5
C3 0/5 0/5 4/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 1/5 1/5 0/5 0/5 0/5 2/5
Table 2.6: Confusion matrix for
Dataset 1 B-PREDICT using RIC.
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Class C1 C2 C3 C4 C5
C1 3/5 0/5 0/5 0/5 0/5
C2 1/5 2/5 0/5 0/5 0/5
C3 0/5 2/5 3/5 0/5 0/5
C4 0/5 0/5 0/5 3/5 1/5
C5 0/5 0/5 0/5 0/5 5/5
Table 2.7: Confusion matrix for
Dataset 2 B-PREDICT using SIC.
Class C1 C2 C3 C4 C5
C1 3/5 0/5 0/5 0/5 0/5
C2 1/5 2/5 0/5 0/5 0/5
C3 0/5 2/5 3/5 0/5 0/5
C4 0/5 0/5 0/5 3/5 1/5
C5 0/5 0/5 0/5 0/5 5/5
Table 2.8: Confusion matrix for
Dataset 2 B-PREDICT using RIC.
2.6 Model challenges for PREDICT and B-PREDICT
Both PREDICT and B-PREDICT seek to encode information on the visible
processes discernible to the viewer for immunosignaturing data. With PREDICT,
the multidimensional PCA execution requires large, robust covariance matrices for
correct PCA. While one shrinkage target is given in equation (2.5), there are multiple
shrinkage targets for data with different structures, as given in [51]. As such, it
is useful to have some prior knowledge of the data itself so that an appropriate
shrinkage target may be selected. Furthermore, using PCA to decrease the overall
dimensionality adds complexity if one is trying to determine which peptides play a
role in each cluster. This is because now individual peptides are not represented
by the dimensionality, but rather these are mapped into the PCA domain and are
represented by combinations of peptides.
In the case of B-PREDICT, specifically dealing with the 2D BPF, while the
drastic feature space reduction is especially favorable for complexity and time, re-
lying solely on PDF shapes can eliminate significant underlying data patterns that
would be useful for classification, especially those whose process is unobserved by the
viewer. As this case uses MLE, it suffers from all drawbacks present in the MLE.
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For example, MLE fitting using single mode PDFs will miss some cases with multi-
modal distributions, or cases were outliers corresponding to biological significance are
present. This is especially true when assuming that there is no initial investigation by
the analyzer into the PDF shape for each microarray, which is a reasonable assump-
tion when dealing with data from many patients. In addition to these drawbacks,
the DP-GMM has some limitations which affect both PREDICT and B-PREDICT.
The first, and probably most important, limitation is that while cluster formation
is potentially infinite, data membership to a given cluster is limited to one. This
would mean that one patient may only be clustered in one group at any given time.
When clusters correspond to disease types, this means that a patient is identified as
having only one disease. Pathogenically it is possible for patients to have reactions to
multiple diseases at any particular time, making the single membership requirement
restrictive. In addition to this issue, the DPGMM only provides information on clus-
tering membership, not on disease identification. In order to associate a particular
disease with a particular cluster and provide patient diagnosis, a well defined train-
ing set would be needed, even though this training set is not required for clustering
itself. Another drawback is that of the a priori assumptions and assignments. The
DP-GMM requires an initial distribution assignment (in this case it is Gaussian) that
is theoretically supposed to model the data well in the parameter space. There may
be other distributions that provide better classification outcomes. This also leads to
assumptions for the innovation parameter α. The a priori value of this innovation
parameter is critical to cluster formation. Setting this value too large or to small
may cause too strict or too loose of group membership associations, thus impacting
the classification. Similarly, the truncation factor M is critical in that selecting a
value too large may unnecessarily and negatively impact overall computation time.
However, setting this parameter too small may result in very large truncation error.
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Algorithm 1 Blocked Gibbs sampling for DP-GMM using an D-dimensional
dataset X
Input: Dataset X = {x1, . . . ,xN}, DP innovation parameter α, Normal-
Wishart hyperparameters µN , τN , ξW , ιW , DP truncation limit M .
Output: Samples {µ(i)m ,Σ(i)m , c(i),w(i)}Li=1
Repeat for i = 1, 2, . . . , Gibbs iterations:
1. Update for θ(i)m = {µ(i)m ,Σ−1(i)m } ∼ p (µm,Σ−1m |c(i−1),X), m = 1, . . . ,M .
(a) Let Xm = {xn : c(i−1)n = m} and Nm = |Xm|, for m = 1, . . . ,M .
(b) For all clusters, m = 1, . . . ,M , compute,
µxm =
1
Nm
∑
n:c
(i−1)
n =m
xn
Σxm =
1
Nm
∑
n:c
(i−1)
n =m
(xm − µxm)2
µ˜N ,m =
τN µ˜N +Nmµxm
τN +Nm
,
τ˜N ,m = τN +Nm ,
ι˜W,m = ιW + Σxm +
τN Nm
τN +Nm
(m− µxm) (m− µxm)T ,
ξ˜W,m = ξW +Nm .
(c) Draw samples for Σ−1(i)m from the Wishart distribution,
W (Σ−1m ; ι˜W,m, ξ˜W,m), for m = 1, . . . ,M .
(d) Finally draw samples for µ
(i)
m from the Normal distribution,
N (µm; µ˜N ,m, Σ
(i)
m
τ˜N ,m
), for m = 1, . . . ,M .
2. Update for c
(i)
n ∼ p (cn|µ(i),Σ−1(i),w(i−1),X), n = 1, . . . , N .
(a) Let qm,n , w(i−1)m N (xn;µ(i)m ,Σ(i)m ), m = 1, . . . ,M and n = 1, . . . , N .
(b) Normalize q′m,n =
qm,n∑M
m=1 qm,n
,m = 1, . . . ,M and n = 1, . . . , N .
(c) Draw samples for c
(i)
n ∼∑Mm=1 q′m,nδ(cn,m), n = 1, . . . , N .
3. Update for w
(i)
m ∼ p (wm|c(i)), m = 1, . . . ,M .
(a) Draw samples βj ∼ Beta
(
1 +N∗m, α+
∑M
m′=m+1 N
∗
m′
)
, where N∗m ,
|{n : c(i)n = m}|, m = 1, . . . ,M .
(b) Finally evaluate w
(i)
m = βm
∏m−1
j=1 (1− βj), m = 1, . . . ,M .
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Chapter 3
CLUSTERING USING BETA PROCESS FACTOR ANALYSIS
The beta process factor analysis (BPFA) model decomposes data into a linear com-
bination of latent features for factors, providing information on the data’s underlying
structure. This is similar to the DP-GMM in that it also relies on a base distribution
to describe the behavior of a parameter space. Unlike the DP, it is based on the beta
process (BP) which is a true completely random measure [75, 84]. With mixture mod-
eling and the DP-GMM, each element could only belong to a single group; this differs
from BPFA where each item may have multiple group membership [53]. This may
lead to the identification of underlying relationships between groups, offering a refined
feature space for the clustering process. Additionally, while the DP-GMM requires a
user specified feature or parameter space in addition to the underlying distributions
as model parameters, BPFA only requires the specification of the underlying model
distributions and learns the number of underlying latent features.
3.1 Beta process theory and related representations
The beta process [85] is useful in Bayesian nonparametric modeling for latent
features [86–88], especially given the implementable conjugate prior relationship in-
herent in the prior. A generalization was presented in [89] where the BP was shown
to be a special case of the kernel beta process. The construction of the beta process
may be described as [86, 90]:
H(Bk) ∼ Beta(αBH0(Bk), αB(1−H0(Bk)) (3.1)
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where k = 1, ..., K are the individual partitions or latent features, Bk is the partition
itself in the space, and αB is a positive scalar. H0 is the continuous probability
measure on the same measurable space. Thus, as K → ∞, Hk → H. Similarly, the
BP has a stick-breaking representation [90, 91]:
θij
iid∼ H0/γ, (3.2)
Vij
iid∼ Beta(1, αB), (3.3)
H(θ) =
∞∑
i=1
Ci∑
j=1
i−1∏
l=1
(1− Vij)δθij , (3.4)
Ci
iid∼ Poisson(γ) (3.5)
where γ = H0({B1...BK}) and iid stands for independent and identically distributed.
While the BP is infinite in feature number, a practical truncation limitation is
often applied to approximate the BP. As the truncation limit increases, it will become
a closer approximation of the theoretical infinite case. A finite approximation and a
two parameter version may be generated [86]:
HK =
K∑
k=1
(pikδφk), (3.6a)
φk
iid∼ H0, (3.6b)
pik ∼ Beta(a/K, b(K − 1)/K), k = 1 . . . K (3.6c)
It should be noted that pi = {pi1, . . . , piK} serves as a new measure of the space, and
it is a parameter for a Bernoulii process, zk,n which will serve as a binary indicator
variable for the latent features to be discovered [86, 92]:
zk,n ∼ Bernoulli(pik) (3.7)
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The combination of Equations (3.6) and (3.7) form a prior for the BPFA.
Another similarly related process is the Indian buffet process (IBP). The structure
is the same as in Equations (3.6) and (3.7), but the second parameter of the beta
distribution, b(K−1)/K simply becomes equal to 1 [92]. While K is indicative of the
truncation coefficient, it is also the maximum number of latent features in BPFA. As
such, it is important for K to be sufficiently large to fully capture the latent feature
interactions within a data set. In practicality, K should not be chosen so large as
to impede quick calculation and convergence for the parameter estimation. The K
value selection is discussed in Section 3.3.
3.2 Beta process factor analysis and blocked Gibbs sampler
As in the case of the DP-GMM, a blocked Gibbs sampler is employed for the
BPFA model parameter estimation. Both a Gibbs sampler method and a variational
Bayes (VB) method can be used to implement BP algorithms [93, 94]. While it
is noted that the Gibbs sampling method may require more iterations to converge
than a VB method [93], its ease of implementation makes it a suitable selection for
immunosignaturing work. Further extensions using collapsed and accelerated Gibbs
sampling with regards to the IBP are discussed in [95]. An MCMC method was
selected for its overall flexibility. The blocked Gibbs sampler was chosen in order
to improve overall performance. The blocked Gibbs sampler also relies heavily on
conjugate priors. In order to construct the algorithm, it is necessary to devise a model
to describe the data that is capable of exploiting these conjugate prior relationships.
Using [53, 86], this BPFA model is described as:
X = ΦZ + E (3.8)
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where X is the immunosignaturing data, matrix Φ and binary matrix Z are parameter
matrices that describe latent features, and E is the error. For a single dataset (i.e.,
patient in the case of immunosignaturing), this can be expressed as:
xn =
K∑
k=1
zk,nφk + e (3.9)
where X = [xT1 . . . x
T
N ] is the (D×N) data matrix, Φ = [φT1 . . . φTK ] is the (D×K)
latent factor matrix, Z = [zT1 . . . z
T
N ] is the (K×N) factor weight binary matrix, and
zn is the (1×K) binary vectors of the nth patient.
A weighted version of this decomposition can be used depending on the re-
quired factor model output [86]. For further discussion, X is considered to be DxN
with D being the data dimensionality and N being the number data points in each
dimensionality. Additionally, Φ is DxK where K is the truncation value or maximum
number of latent features. Finally, Z is KxN and E is DxN . The additional inter-
mediate random variable pi is used as a precursor for describing Z per equation (3.7).
For this model, Z is considered to be Bernoullli distributed, pi is Beta distributed, Φ
is Gaussian, and the variance of the error E is Inverse-Gamma. This makes X also
Gaussian with a mean of ΦZ and a variance of σ2eI where I is the identity matrix.
The model parameter relationships are described as [86]:
X ∼ N (ΦZ, σ2eI), (3.10a)
σ2e IΓ(c, d), (3.10b)
φk ∼ N (0,Σφk), (3.10c)
zk,n ∼ Bernoulli(pik), (3.10d)
pik ∼ Beta(α, β) (3.10e)
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Figure 3.1: BP block diagram.
where n refers to the nth element of N data points, φk refers to the kth column of
Φ, and zk,n refers to the nth element of the kth row of the Z matrix. The relationship
between these random variables is given in Figure 3.1.
The conjugate prior relationships are the basis for the MCMC technique con-
sidered here for BPFA. When this is applied to the blocked Gibbs sampler framework
for each of the BPFA parameters for the ith iteration, this becomes:
pi
(i)
k ∼ p(pi|Z(i−1), α(i)0 , β(i)0 ), k = 1 . . . K, (3.11a)
φ
(i)
k ∼ p(φk|Φ(i−1),Z(i−1), σ2e (i−1),X), k = 1 . . . K, (3.11b)
z
(i)
k,n ∼ p(zi,k|Φ(i),Z(i−1), σ2e (i−1), pi(i),X), k = 1 . . . K, n = 1 . . . N, (3.11c)
σ2e
(i) ∼ p(σ2e |Φ(i),Z(i), σ2e (i−1),X) (3.11d)
There are also hyperparameters (az, bz, cz, and dz) that are also updated in the blocked
Gibbs sampler, but they utilize different priors and are conditional functions of both
the initialized value for each hyper-parameter, as well as the other estimated matrices
in each iteration. These hyper-parameters are used to describe other distributions and
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are only indirectly related to the estimated model parameters of interest. It should
be noted that the update order within the blocked Gibbs sampler does not matter as
long as the most recent updates are used for each new estimation. The blocked Gibbs
sampler algorithm with specific update equations for BPFA is given in Algorithm 2.
Noting that ||·|| is the norm of the expression, combined together, this provides
the following conditional PDFs:
β-distributed pi
(i)
k ,
β
(
pi
(i)
k ; a
(i)
z , b
(i)
z
∣∣ Z(i−1), a, b) (3.12)
a(i)z =
a
K
+
N∑
n=1
z
(i−1)
k,n (3.13)
b(i)z =
b(K − 1)
K
+N −
N∑
n=1
z
(i−1)
k,n , (3.14)
Gaussian distributed φ
(i)
k ,
g
(
φ
(i)
k ;µ
(i)
φ , Σ˜
(i)
φ
∣∣ Φ(i−1),Z(i−1), σ2 (i−1)e ,X) (3.15)
Σ˜
(i)
φ =
(
z
(i−1)
k z
T,(i−1)
k ID σ
−2 (i−1)
e + Σ
−1
φ
)−1
(3.16)
µ
(i)
φ =
[(
z
(i−1)
k z
T (i−1)
k IDσ
−2 (i−1)
e + Σ
−1
φ
)−1
σ−2 (i−1)e
N∑
n=1
z
(i−1)
k,n
K∑
k′=1
k′ 6=k
z
(i−1)
k′,n φ
T (i−1)
k′
]
, (3.17)
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where zk is the kth row of Z and Bernoulli distributed z
(i)
k,n
Bernoulli
(
z
(i)
k,n;ψ
(i)
∣∣Φ(i),Z(i−1), σ2 (i−1)e ,pi(i),X) (3.18)
ψ(i) =
1 + 1− pi(i)k
pi
(i)
k
exp
(σ2e)(i−1)2
∥∥∥∥∥∥∥∥xn −
K∑
k′=1
k′ 6=k
z
(i−1)
k′,n φ
(i)
k′
∥∥∥∥∥∥∥∥
2
−
∥∥∥∥∥∥∥∥xn − φ
(i)
k −
K∑
k′=1
k′ 6=k
z
(i−1)
k′,n φ
(i)
k′
∥∥∥∥∥∥∥∥
2

−1
, (3.19)
and inverse Gamma distributed σ
2 (i)
e ,
IΓ
(
σ2 (i)e ; c
(i)
z , d
(i)
z
∣∣∣ Φ(i),Z(i),X) (3.20)
c(i)z = c+ (ND/2) and (3.21)
d(i)z = d+
1
2
N∑
n=1
∥∥∥∥∥xn −
K∑
k′=1
z
(i)
k′,nφ
(i)
k′
∥∥∥∥∥
2
. (3.22)
3.3 Selection of K for BPFA
The remaining item to be defined for BPFA for the immunosignaturing model
is the selection of the user defined truncation parameter K. When using this model
and referring to pi in both Equation (3.10) and (3.6), α0 and β0 are defined as [86]:
α0 =
a
K
, (3.23a)
β0 =
b(K − 1)
K
(3.23b)
where a and b are similar to the innovation parameter α in the DP-GMM. In the
BPFA, these parameters help to define the multi-feature presence of each item to
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Algorithm 2 Blocked Gibbs sampling for BPFA using an D-dimensional
dataset X
Input: Dataset X = [x1, . . . ,xN], beta process positive scalars a and b, the
truncation limit K, and inverse gamma hyperparameters c and d.
Output: Samples {pi,Φ,Z,σ2e}Lj=1 from the posterior pdf P (pi,Φ,Z,σ2e|X).
Repeat for j = 1, 2, . . . , Gibbs iterations:
1. Update for {pik} ∼ β
(
pi
(i)
k ; a
(i)
z , b
(i)
z
∣∣ Z(i−1), a, b), k = 1 . . . K
(a) Draw: β
(
pi
(i)
k ;
a
K
+
∑N
n=1 z
(i−1)
k,n ,
b(K−1)
K
+N −∑Nn=1 z(i−1)k,n ∣∣ Z(i−1), a, b)
2. Update for {zk} ∼ Be
(
z
(i)
k,n;ψ
(i)
∣∣Φ(i−1),Z(i−1), σ2 (i−1)e ,pi(i),X), k =
1 . . . K .
(a) Draw: Be
z(i)k,n;
1+ 1−pi(i)kpi(i)k exp
 (σ2e)(i−1)2 ∥∥∥∥xn −∑Kk′=1
k′ 6=k
z
(i−1)
k′,n φ
(i−1)
k′
∥∥∥∥2−
∥∥∥∥xn− φ(i−1)k −∑Kk′=1
k′ 6=k
z
(i−1)
k′,n φ
(i−1)
k′
∥∥∥∥2


−1∣∣∣∣∣∣∣∣Φ
(i−1),Z(i−1), σ2 (i−1)e ,pi(i),X

3. Update for {Φ} ∼ g(φ(i)k ;µ(i)φ , Σ˜(i)φ ∣∣ Φ(i−1),Z(i), σ2 (i−1)e ,X), k=1 . . . K
(a) Draw: g
(
φ
(i)
k ;µ
(i)
φ , Σ˜
(i)
φ
∣∣Φ(i−1),Z(i), σ2 (i−1)e ,X).
(b) Define: Σ˜
(i)
φ =
(
z
(i)
k z
T,(i)
k ID σ
−2 (i−1)
e + Σ
−1
φ
)−1
(c) Define: µ
(i)
φ =
[
Σ˜
(i)
φ σ
−2 (i−1)
e
∑N
n=1z
(i)
k,n
∑K
k′=1
k′ 6=k
z
(i)
k′,nφ
T (i−1)
k′
]
4. Update for {σ2e} ∼ IΓ
(
σ
2 (i)
e ; c
(i)
z , d
(i)
z
∣∣∣ Φ(i),Z(i),X)
(a) Draw: IΓ
(
σ
2 (i)
e ; c
(i)
z , d
(i)
z
∣∣∣ Φ(i),Z(i),X)
(b) Define: c
(i)
z = c+ (ND/2)
(c) Define: d
(i)
z = d+ 12
∑N
n=1
∥∥∥xn −∑Kk′=1 z(i)k′,nφ(i)k′ ∥∥∥2
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Figure 3.2: Example distributions for K truncation selection.
be classified. Thus, while K is user defined, there is an interrelationship between a,
b, and K that affects the latent feature groupings during estimation. Furthermore,
truncation of K far below the true underlying feature amount will result in sub-
optimal latent feature memberships, further affecting the classification. As such, it is
desired to know approximately the value of K. Further complicating the selection is
the interaction of N , which is defined by the input data, on the Poisson distribution
indicated in Equation (3.2). This interaction is given as [86]:
λP =
N∑
n=1
a
b+ n− 1 (3.24)
where λP is the parameter for the Poisson distribution. An example of this effect is
given in Figure 3.2. Thus, one should select a value of K that encompasses enough
of the Poisson distribution specified by the parameter given in Equation (3.24).
The IBP has very similar functionality to the BPFA algorithm in that a beta
process prior is used as in equation (3.6c), but the innovation parameters are changed
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such that α0 = a/K but β0 = 1 [92]. The link between the IBP and the beta process
may be thought of as CRP:DP::IBP:BP [96]. Further discussion of the IBP may be
found in [97].
3.4 BPFA and immunosignaturing input data format
When dealing with immunosignaturing data, there are at least two possible
use cases for analysis of incoming patient data. While each case does not impact how
the BPFA is modeled or executed, it does impact how the input data is used within
the BPFA. In each case, it will effectively change the random variable that is used
to further classify patients based on underlying disease state. In this work, reduction
in the number of peptides for analysis is performed by using either PCA or BPF as
discussed in Sections 2.1 and 2.2. Further refinement is then done by the BPFA.
In the first format, the feature model still follows the format of Equations
(3.8) and (3.10), but the dimension D is defined as the number of patients while the
number of data points N is defined as the microarray intensity measurements, or some
dimensionality reduction thereof, for each patient. This case would be useful when
additional microarray data points are received for patients over time, but the overall
number of patients does not change. This then means that the estimated value of the
Φ matrix, represented as Φˆ, and found after using the blocked Gibbs sampler, would
be the parameter that describes the relationship between patients and underlying
features. It is these latent features that are thought to represent the underlying
states (i.e. diseases) for patients. In this case, the estimated Z matrix, hereafter
represented as Zˆ, would represent the relationship between peptides or combinations
of peptides (after dimensionality reduction) to latent features.
In the second format, which also follows the general model structure given
in Equations (3.8) and (3.10), dimensionality D is defined as the number of peptide
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sequences, or peptide sequence combinations after dimensionality reduction. This
then means that N is defined as the number of patients being analyzed. For this case,
the Φˆ matrix from the blocked Gibbs sampler iterations will illustrate the relationship
between latent features and peptides (or peptide combinations after dimensionality
reduction). This may be used to show which peptide or peptide combinations play a
role in various disease states, similar to how the Zˆ matrix was used in the previous
format. This then means that the Zˆ matrix derived from the execution of the blocked
Gibbs sampler may be use to highlight the underlying feature representations for each
patient, and thus the underlying disease state for each patient. This is similar to how
the Φˆ matrix was used in the previous format.
3.5 Clustering Using BPFA
3.5.1 BPFA with Z-matrix and PCA Features
Once the Φˆ and Zˆ matrices are found from BPFA, it is possible to use a variety
of classification or clustering schemes to determine patient groupings based on dis-
eases. The first is the Z-PREDICT or Z-matrix from PCA REsolution and Discovery
for Immunosignature Classification Testing, uses the log of the PCA feature space as
first presented in PREDICT as the input to the BFPA. Since the Zˆ matrix is a binary
feature matrix, features are either present, as represented by a 1, or not present, as
represented by a 0.
If there are not too many latent features found during BPFA application, then
it may be possible to simply inspect the feature combinations and determine which
patients contain similar feature representations. This can be time consuming as the
data grows, and therefore a more formal representation is desired. However, the Zˆ
matrix then needs to be modified such that incorrect comparisons can be penalized
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without negatively impacting correct correlation matches. This is accomplished by
replacing all zero entries with a negative one, and is known then as the matrix Y.
The replacement of these strategic values introduces the concept of penalty and re-
ward criteria for the Zˆ matrix which can be modified depending on the clustering
problem. This matrix is then multiplied by the transpose of itself to find the feature
vector correlations amongst all vectors. This can mathematically be described as the
following modifications to the Z matrix:
Y = (2Z− 1), (3.25a)
C = YTY (3.25b)
This may also be thought of as taking the non-normalized dot product of
each K dimensional binary feature vector with every other binary feature vector.
Individual comparisons with high C values are more likely to be classified together
correctly. For example, consider the Zˆ matrix given in Figure 3.3. This matrix
is presented in left ordered form (LOF) [92] and is transposed for readability with
features being all zeros removed. Each patient has an associated set of features that
may be represented by a binary feature vector.
For example, consider patient 1 whose binary feature vector is z1 = [1, 1, 0, 0, 0, 0].
After equation (3.25a), this becomes y1 = [1, 1,−1,−1,−1,−1]. In order to see if
this patient should be clustered with patient 2, whose modified binary feature vector
is y2 = [1, 1,−1,−1,−1,−1], find the correlation (or dot product) of these two vec-
tors. The result of this correlation is y1 · y2 = 6. Now, compare the modified binary
feature vector for patient 1 with that for patient 25 (y25 = [−1, 1,−1,−1,−1, 1]); the
correlation in this case is four. Since the correlation between patient 1 and patient
25 is lower than the correlation between patient 1 and patient 2, it is more likely
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Figure 3.3: Example Zˆ matrix
that patient 1 and patient 2 should be clustered together than patient 1 and patient
25. This pairwise comparison may be done for all the patients and a ranking of their
correlations may be achieved.
3.5.2 BPFA with Z-matrix and Beta PDF Fitting Features
In Z-PREDICT, PCA was used for dimensionality reduction. Similarly, BPF
may be used as well as described in section 2.2. In the ZB-PREDICT method (Z-
matrix from BPDF REsolution and Discovery for Immunosignature Classification
Testing), scaled BPF is used to reduce the immunosignature data dimensionality.
This is then fed into the BPFA for latent feature discovery. The latent feature binary
Zˆ matrix is then modified according to equation (3.25a). Again, the higher the C
value, the more likely two patients are to be grouped together due to the fact that
their latent feature spaces are closer matches to one another, as is seen when using
the Z matrix modifications to penalize incorrect matches.
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3.5.3 BPFA with Φ Matrix and PCA
Another method, Φ-PREDICT, may be used to determine patient cluster-
ing by disease as well. This is also known as Φ PCA REsolution and Discovery
for Immunosignature Classification Testing. As previously discussed, this requires
the input data matrix to be transposed from that discussed in Z-PREDICT or ZB-
PREDICT. As opposed to previous methods, Φˆ (the MCMC estimate of Φ) is a
non-binary feature matrix governed by the distribution given in equation (3.10). Due
to the non-binary nature of this matrix, it may be more difficult to determine patient
groups by simple inspection. As such, a simple quantization scheme may be employed
to determine patient groups. Each latent feature may be assigned to a pre-determined
user specified quantization level. This will lead to a quantized version of Φˆ, which
means that each patient will have different quantized latent feature representations.
By inspection, it will be possible to see which patients contain feature combinations
at identical quantization levels and group these patients together. It should be noted
that the results from the Φˆ matrix may be fed into the DP-GMM for further adaptive
classification. This was not investigated in this work due to other positive results
using alternative methods.
It should be noted that there is still an RIC and SIC application for these
classification results. However, since the Φ-PREDICT method is much more user
involved in terms of specifying clustering parameters, the definition of SIC and RIC
are slightly changed. SIC is still the exact match of all features but now is extended
to all quantization levels. The definition of RIC is more user specific. For RIC, it is
still the matching of features, but in this case the user may elect to allow for some
variation amongst features that do not match. This can be though of as allowing
the majority of features to be correctly matched (example results in [44], which were
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produced before the inception of RIC and SIC), or it may be thought of as allowing
feature variance within a certain number of quantization levels. Additionally, as the
number of examined features increases, the less likely they are to match at every
quantization level all the time, making the analysis overly restrictive.
3.6 BPFA Clustering Results
3.6.1 Results of BPFA with PCA Features
In this case, the input data matrix to the BPFA will be transposed. This means
that D is the number of peptide combinations selected from the PCA of the median
intensity data, and N is the number of patients. For Dataset 1 the resulting Φˆ and Zˆ
matrices as well as the estimated reordered pik values are presented in Figure 3.4. The
Zˆ matrix is in the LOF configuration [92] and transposed. Features containing no
entries were removed in order to easily show the feature relationships. In this case, it
is the Φˆ matrix that illustrates the relationship between the peptide combinations and
underlying features and Zˆ illustrates the relationship between features and patients.
Three PCA components were used in this analysis which represents 93.5% of the data
and K = 50. A total of 2000 burn-in iterations and 3000 sample iterations were used
for the blocked Gibbs sampler. The confusion matrices for SIC and RIC cases are
given in Tables 3.1 and 3.2. The SIC result was 60% and the RIC result was 73.3%.
For Dataset 2 the resulting Φˆ, Zˆ, pik are presented in Figure 3.5. Once again,
Zˆ is presented in LOF configuration, transposed, and with features have zero entries
removed. Five PCA components were used for this analysis which accounts for 93.5%
of the data and K = 50 for this analysis. A total of 3000 burn-in iterations and 3000
sample iterations were used. The resulting SIC and RIC were both 88%.
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Figure 3.4: BPFA results from Dataset 1
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Figure 3.5: BPFA for Dataset 2
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Figure 3.6: Z-PREDICT classification results.
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Class C1 C2 C3 C4 C5 C6
C1 3/5 0/5 0/5 0/5 0/5 0/5
C2 0/5 3/5 0/5 0/5 1/5 0/5
C3 1/5 0/5 3/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 2/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 1/5 2/5
Table 3.1: Dataset 1 confusion matrix
for Z-PREDICT using SIC.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 0/5 3/5 0/5 0/5 1/5 0/5
C3 1/5 0/5 3/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 1/5 2/5
Table 3.2: Dataset 1 confusion matrix
for Z-PREDICT using RIC.
Class C1 C2 C3 C4 C5
C1 4/5 0/5 0/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5
C4 1/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 3.3: Dataset 2 confusion matrix
for Z-PREDICT using SIC.
Class C1 C2 C3 C4 C5
C1 4/5 0/5 0/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5
C4 1/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 3.4: Dataset 2 confusion matrix
for Z-PREDICT using RIC.
3.6.2 Results of BPFA with Beta PDF Fitting Features
Two datasets were analyzed with ZB-PREDICT. The results of the BPFA
may be seen in Figures 3.7 and 3.8 for Dataset 1 and 2 respectively. For Dataset 1,
K = 50 was used along with 2000 burn-in iterations and 2000 sample iterations. The
Resulting RIC and SIC were 83.3% for both. For Dataset 2, K = 50 was used along
with 2000 burn-in and 2000 sample iterations. This resulted in 76% RIC and SIC.
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(b) Zˆ matrix transposed, in LOF null features
removed for Dataset 1.
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Figure 3.7: ZB-PREDICT BPFA results from Dataset 1
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Figure 3.9: ZB-PREDICT clustering results.
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Figure 3.8: ZB-PREDICT BPFA results from Dataset 2
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 3/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 3/5 0/5 0/5 0/5 0/5 2/5
Table 3.5: Dataset 1 confusion matrix
for ZB-PREDICT using SIC.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 3/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 3/5 0/5 0/5 0/5 0/5 2/5
Table 3.6: Dataset 1 confusion matrix
for ZB-PREDICT using RIC.
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Class C1 C2 C3 C4 C5
C1 5/5 0/5 0/5 0/5 0/5
C2 2/5 1/5 2/5 0/5 0/5
C3 0/5 0/5 4/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 3.7: Dataset 2 confusion matrix
for ZB-PREDICT using SIC.
Class C1 C2 C3 C4 C5
C1 5/5 0/5 0/5 0/5 0/5
C2 2/5 1/5 2/5 0/5 0/5
C3 0/5 0/5 4/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 3.8: Dataset 2 confusion matrix
for ZB-PREDICT using RIC.
3.6.3 Results of BPFA with Φ Matrix and PCA
As previously stated, data matrix X is of size DxN . When patients are used
as the dimensionality of this matrix, D, this means that the input data matrix must
be arranged such that the rows of the matrix contain the N peptide PCA components
desired. The simplistic quantization scheme as described in section 3.5.3 was utilized
for classification. For these results, RIC is defined as having the exact same features
at the exact same quantization levels with the except of a single feature that is within
a single quantization level of the rest of the group.
For Dataset 1 the resulting Φˆ and Zˆ matrices as well as the estimated pik values
are reordered and presented in Figure 3.10. The Zˆ matrix is presented in left ordered
form (LOF) [92] and are transposed with features containing no entries removed in
order to easily show the feature relationships. In this case, it is the Φˆ matrix that
illustrates the relationship between the patients and underlying features. It is possible
to see that the combinations of underlying features are indicative of the disease states
of each of the patients. A simple classification scheme is included in Figure 3.11 for
dataset 1 that is produced by simple quantization of the values of each entry in the
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matrix. Also shown in this figure is the comparison of every patient to every other
patient for both a scaled and unscaled image. The number of PCA components used
in this analysis was 31 which represents 99.93% of the data and K = 50 for this
analysis. A total of 2500 burn-in iterations and 2500 sample iterations were used for
the blocked Gibbs sampler. The confusion matrices for the SIC and RIC cases are
given in Tables 3.9 and 3.10. This led to a SIC result of 43.3% and a RIC result
of 53.3%. For Dataset 2 the resulting Φˆ, Zˆ, pik are presented in Figure 3.12. Once
again, Zˆ is presented in the LOF configuration, transposed, and with features having
zero entries removed. The simple classification scheme is shown in Figure 3.13 which
is produced from simple quantization of the values of each entry in the Φˆ matrix.
The number of PCA components used in this analysis was 26 which accounts for
essentially 100% of the data and K = 50 for this analysis. A total of 2000 burn-in
iterations and 2000 sample iterations were used. The SIC and RIC confusion matrices
are given in Table 4.3 and 4.3 respectively. SIC was 60% while RIC was 68%.
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Figure 3.10: BPFA output for Dataset 1
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Figure 3.11: Dataset 1 Φ-PREDICT results
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Figure 3.12: BPFA output for Dataset 2
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Figure 3.13: Φ-PREDICT results for Dataset 2
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Class C1 C2 C3 C4 C5 C6
C1 2/5 0/5 0/5 0/5 0/5 0/5
C2 0/5 1/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 1/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 2/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 0/5 0/5 0/5 2/5
Table 3.9: Dataset 1 confusion matrix
for Φ-PREDICT results using SIC.
Class C1 C2 C3 C4 C5 C6
C1 2/5 0/5 0/5 0/5 0/5 0/5
C2 0/5 3/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 2/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 2/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 0/5 0/5 0/5 2/5
Table 3.10: Dataset 1 confusion ma-
trix for Φ-PREDICT results using
RIC.
Class C1 C2 C3 C4 C5
C1 1/5 0/5 0/5 3/5 0/5
C2 0/5 1/5 1/5 3/5 0/5
C3 0/5 0/5 4/5 1/5 0/5
C4 0/5 0/5 0/5 5/5 0/5
C5 0/5 0/5 1/5 0/5 4/5
Table 3.11: Dataset 2 confusion ma-
trix for Φ-PREDICT results using
SIC.
Class C1 C2 C3 C4 C5
C1 1/5 0/5 0/5 3/5 0/5
C2 0/5 1/5 1/5 3/5 0/5
C3 0/5 0/5 5/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 3.12: Dataset 2 confusion ma-
trix for Φ-PREDICT results using
RIC.
3.7 Challenges with BPFA Clustering
Several challenges to these classification schemes exist, the first of which is
the increased computational overhead as the number of patients increases; in other
words, a larger C matrix is generated. Additionally, as K increases, the C values
may increase, leading to an artificial inflation of the values simply due to more shared
features. Thus, it will not be possible to compare C values from different dataset runs
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when new BPFA results are generated, though this may be solved by normalizing the
resulting feature vectors. Additionally, the quantization scheme for Φ-PREDICT
is user specified and its performance is dependent on the appropriate level being
employed. If there are too many quantization levels used, then it is less likely that
patients with similar diseases will have the exact same features at the exact same
quantization levels due to too fine resolution. If there are too few quantization levels,
there is the possibility that patients with different diseases will have similar feature
representations at identical quantization levels due to too poor resolution.
Furthermore, extra care is needed when determining what will be considered
correct classification using this method. Definitions for SIC are fairly straightforward,
but when considering RIC, the user must select appropriate amounts of variation that
will be considered allowable in the final classification analysis. This is often tied to
the classification parameters selected such as number of quantization levels or number
of features considered. As such, this creates a highly variable picture as to what can
be considered correct classification, and may need to be considered on a case by case
basis, depending on how the output will be used. This can also lead to different
interpretations for SIC and RIC criteria as well. For example, it might be perfectly
acceptable in a research or discovery setting to allow for some variation in the feature
quantization levels, where as in the clinical setting, one may want to go with the SIC
definition as clinical action will be taken based on the results.
For this reason, matrices comparing each output to that of every other output
are provided for easier results viewing. It is possible that further analysis on these
comparison matrices (such as thresholding for what will be considered correct classi-
fication) would yield additional insights into the classification results. Additionally,
all of these methods are non-adaptive and do not easily allow additional patient data
to be analyzed; this method was not further explored within the context of this work.
68
While the BPFA is very useful in highlighting underlying feature relationships,
it does not inherently perform classification for immunosignaturing data based on
the less restrictive definition that multiple features may describe a disease state.
For example, once having found the Φˆ and Zˆ matrices in each case, it may not
be intuitively obvious which patients should be grouped together. This is especially
difficult as the number of features increases. As such, further classification algorithms
may still be needed to illustrate the patient groupings. Additionally, the number of
estimated parameters is much greater than in the DP-GMM based methods previously
discussed, which leads to increased computational complexity and execution time.
While improvements in these areas are not the focuses of this work, it is possible to
further refine the algorithms, such as by the implementation of parallel architectures,
to improve the BPFA execution.
With regards to the BPFA model parameters themselves, the prior distribu-
tion assumptions were also selected in this case to provide some nice conjugate prior
simplifications. Other distributions may be selected that could be more appropriate
to the data types and improve the subsequent classification. Additionally, the inno-
vation parameters a and b (and the equation related K) play a role in how latent
features are grouped together. Therefore, it is possible to select these parameters
such that features are not usually grouped together or such that they are very often
grouped together. The user input is somewhat critical for these parameters, and they
should be carefully selected based on how conservative one needs to be in terms of
missclassification.
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Chapter 4
INTEGRATED DP-GMM AND BPFA CLUSTERING
4.1 Integration of DP-GMM Clustering with BPFA Latent Feature Analysis
While beta process factor analysis (BPFA) allows for the determination of
underlying features that describe the patient, disease, antibody, and peptide rela-
tionships measured by immunosignaturing, it requires a clustering scheme in order
to group the latent features. This is because clustering is based on combinations of
features rather than the more restrictive assumption of one feature corresponding to
one cluster only. Although the heuristic clustering schemes discussed in Chapter 3
using the Φˆ and modified Zˆ matrices as estimations of Equation (3.8) were success-
fully used, their expansibility and utility is somewhat limited. This is because the
heuristic clustering algorithms become increasingly difficult to use as the number of
features, patients, or patient data increases. As such, an adaptive method like the
DP-GMM may be used to perform the clustering.
A combined approach using the Dirichlet Process (DP) and BPFA is used to
learn a dictionary for image construction in [98], but does not focus on identifying
latent features. In [46], an infinite overlapping mixture model was used by assigning
data to multiple clusters following the Indian buffet process (IBP), assuming under-
lying features as clusters, but this is too restrictive for immunosignatures. In [99],
a combined beta process DP model was considered for a compressive sensing frame-
work, but it doesn’t consider both visible and latent processes. A further use of the
DP with the IBP is described in [45], which assumes that there are multiple clustering
interpretations for the resulting features rather than a single grouping.
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4.1.1 DP-GMM and BPFA Clustering Using PCA Features
The same DPGMM algorithm presented in Algorithm 1 may be used to adap-
tively classify both the Φˆ or the Zˆ matrices in order to show patient groups that
indicate similar disease states. The BIO-PREDICT, or BPFA Included prOcessing
with PCA REsolution and DPGMM for Immunosignature Classification Testing,
combines PCA dimensionality reduction with the BPFA for latent feature identifi-
cation, and then feeds the result of the Zˆ matrix into the DPGMM for adaptive
clustering. In terms of immunosignaturing, this method provides a flexible, adaptive
method for on-the-fly clustering that is applicable in the situation where additional
data for new patients is received, or when additional immunosignaturing data for
existing patients is received. This method does not require any modification of the
existing BPFA or DPGMM algorithms, making it a good fit and logical next step
for the immunosignaturing clustering problem. The combination of these two meth-
ods allows for complex feature relationships that are algorithmically determined via
Bayesian nonparametrics rather than described by only the observable data charac-
teristics available to the researcher. Additionally, since the clustering is adaptive, it
is able to update model parameters and adjust to new incoming data.
4.1.2 DP-GMM and BPFA Clustering Using Beta PDF Fitting Features
Just as PCA was used for dimensionality reduction in BIO-PREDICT, the beta
probability density function fitting (BPF) can be used to obtain the BIOB-PREDICT,
or BPFA Including prOcessing using Beta PDF REsolution with DPGMM for
Immunosignature Classification Testing algorithm. This approach uses beta PDF
fitting for feature reduction, followed by BPFA for latent feature identification, and
a reduced and transposed Zˆ matrix is then fed into the DP-GMM for adaptive clus-
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tering. This method provides an alternative to PCA in the BIO-PREDICT method,
thereby limiting the feature space to two dimensions for all patient samples.
4.2 Clustering Results for Integrated Clustering Approaches
4.2.1 Results of DP-GMM with BPFA and PCA
Several datasets were analyzed using the BIO-PREDICT method. For Dataset
1, the Z-PREDICT BPFA results given in Figure 3.4 were used as the input for BIO-
PREDICT (as opposed to running the same data from the PCA stage). For the
remaining DPGMM stage, α = 35 was chosen, the number of burn-in iterations was
2000, and the number of sample iterations was 3000. For the Dataset 2, the BPFA
results of Z-PREDICT in Figure 3.5 were used. The remaining DPGMM step used
α = 45, and 2000 burn-in iterations and 3000 sample iterations were used. The re-
sults of the clustering are seen in Figures 4.1(a) and 4.1(b), and the corresponding
confusion matrices are seen in Tables 4.1, 4.2, 4.3, and 4.4. The clustering result for
this was found to be 76.7% for both SIC and RIC for Dataset 1 and 88% for both
SIC and RIC for Dataset 2.
Class C1 C2 C3 C4 C5 C6
C1 0/5 1/5 1/5 3/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5 0/5
C3 0/5 1/5 3/5 0/5 0/5 0/5
C4 1/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 0/5 3/5
Table 4.1: Dataset 1 confusion matrix
for BIO-PREDICT using SIC.
Class C1 C2 C3 C4 C5 C6
C1 0/5 1/5 1/5 3/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5 0/5
C3 0/5 1/5 3/5 0/5 0/5 0/5
C4 1/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 0/5 0/5 2/5 0/5 0/5 3/5
Table 4.2: Dataset 1 confusion matrix
for BIO-PREDICT using RIC.
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Figure 4.1: BIO-PREDICT results
Class C1 C2 C3 C4 C5
C1 4/5 0/5 0/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5
C4 1/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 4.3: Dataset 2 confusion matrix
for BIO-PREDICT using SIC.
Class C1 C2 C3 C4 C5
C1 4/5 0/5 0/5 0/5 0/5
C2 0/5 4/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5
C4 1/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 4.4: Dataset 2 confusion matrix
for BIO-PREDICT using RIC.
4.2.2 Results of DP-GMM with BPFA and Beta PDF Fitting
The BIOB-PREDICT algorithm was performed using the BPFA outputs given
in Figures 3.7 and 3.8. For the remaining DPGMM step for Dataset 1, α = 35, 2000
burn-in iterations, and 3000 sample iterations were used. This results in a SIC and
RIC clustering rate of 83.3% in both cases. For Dataset 2, the remaining DPGMM
steps used α = 35, 2000 burn-in iterations, and 2000 sample iterations. For this data
set, the SIC and RIC clustering results were both 76%.
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(a) BIOBPREDICT results from Dataset 1.
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(b) BIOBPREDICT results from Dataset 2.
Figure 4.2: BIOB-PREDICT clustering results.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 3/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 3/5 0/5 0/5 0/5 0/5 2/5
Table 4.5: Dataset 1 confusion matrix
for BIOB-PREDICT using SIC.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 2/5 3/5 0/5 0/5 0/5 0/5
C3 0/5 0/5 5/5 0/5 0/5 0/5
C4 0/5 0/5 0/5 5/5 0/5 0/5
C5 0/5 0/5 0/5 0/5 5/5 0/5
C6 3/5 0/5 0/5 0/5 0/5 2/5
Table 4.6: Dataset 1 confusion matrix
BIOB-PREDICT using RIC.
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Class C1 C2 C3 C4 C5
C1 5/5 0/5 0/5 0/5 0/5
C2 2/5 1/5 1/5 0/5 0/5
C3 0/5 0/5 4/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 4.7: Dataset 2 confusion matrix
BIOB-PREDICT using SIC.
Class C1 C2 C3 C4 C5
C1 5/5 0/5 0/5 0/5 0/5
C2 2/5 1/5 1/5 0/5 0/5
C3 0/5 0/5 4/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 4.8: Dataset 2 confusion matrix
for BIOB-PREDICT using RIC.
4.3 BIO-PREDICT and BIOB-PREDICT Model Challenges
For BIO-PREDICT, the PCA steps require correct eigenvalue truncation, as
well as the assumption that the data can be maximized along orthogonal basis. The
modified covariance matrix also requires an understanding of the underlying data in
order to select an appropriate shrinkage factor. These challenges require additional
user analysis and input. For the BIOB-PREDICT algorithm, the BPF step results
in a large amount of data loss when reducing to two parameters, and assumes that
the feature space is sufficient to capture subtle antibody differences. For both BIO-
PREDICT and BIOB-PREDICT, while using the DP-GMM is an improvement over
the proposed simple clustering schemes in that it is adaptive, it still has its own chal-
lenges (see section 2.6). The issues with innovation parameter selection, underlying
distribution selection (Gaussian), and single cluster membership are tradeoffs. Addi-
tionally, the BPFA steps require the selection of a distribution and feature parameters,
and while a version is presented here, other distributions may be more suited to the
data. Thus, both methods can prove to be computationally intensive when evaluated
using the blocked Gibbs sampler method in a Markov chain Monte Carlo framework.
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Chapter 5
MULTIPLE STATE CLUSTERING USING BPFA
5.1 Motivation for Multiple Disease State Clustering
It has been shown that it is possible to model and cluster immunosignaturing
data using Bayesian nonparametric techniques such as Dirichlet process Gaussian mix-
ture modeling (DP-GMM) and the beta process factor analysis (BPFA) when these
are incorporated into a broader algorithm flow. The previously presented cluster-
ing algorithms assume only patients with a single state, or single underlying disease.
However, there may be instances when clustering or classification into multiple un-
derlying states is necessary. For example, a patient may suffer from more than one
disease or multiple strains of the same disease [40].
There is also a desire not only to determine patient pathology groupings, but
also to determine pathology combinations in patients (i.e., the presence of multiple
diseases). Other possible examples include the desire to identify a single disease as well
as the disease stage, the need to illustrate single disease relationships where multiple
relationships are possible with other diseases, and the desire to know both diseases
and symptoms. Additionally, there may be relationships between single diseases or
disease manifestations (such as expanded relaxed immunosignaturing classification,
RIC, criteria) that are not explored when a single group is assigned. As such, ad-
ditional algorithms need to be developed to allow multiple cluster membership for a
single patient sample. Furthermore, while clustering was successful in previous re-
sults, there was no disease identification determined; results are restricted to only the
basic groupings amongst patients.
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There is a desire to extend the single state techniques to accommodate for
multiple underlying states and provide flexibility for further analysis. We propose to
modify the heuristic Z matrix based clustering algorithms in Chapter 3 for determin-
ing multi-state relationships amongst patients by introducing known information for
desired states [48]. This may also be thought of as training data required for state
identification but is not used for clustering. In the case of disease data, this would
mean immunosignatures that are associated with a known disease state.
5.2 Algorithms for Multiple State Clustering Based on BPFA
5.2.1 PCA Features with BPFA for Multiple State Clustering
Previously, it was demonstrated that it is possible to separate patient groups
using the Z-PREDICT algorithm and further using the BIO-PREDICT algorithm
to facilitate easier clustering. The inputs in both of these cases were log PCA data
based on individual patient immunosignatures consisting of the median intensities of
peptide sequences on the microarray. The combinations of latent features were used
to define a single disease state, where more than one feature may be indicative of
a particular patient group. However, these algorithms will only indicate underlying
feature combinations; they do not directly separate out which feature combination
pertains to which disease unless a training set of data is available. This training
data, or disease key data, is necessary for diagnosis in order to establish the baseline
responses for known states.
In order to expand Z-PREDICT to be useful for n underlying states, some
equation modifications need to be made. As such, the Z-PREDICTn, or Z-matrix
from PCA REsolution and Discovery for Immunosignature Classification Testing
up to n-states, algorithm is developed. In this method, a master key for single states
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(i.e., training data for the single state) is used to compare against the individual data
entries with multiple underlying states. The algorithm is built upon the basis that
the latent features for multi-state patients are some mathematical operation between
the feature vectors for the individual states. For example, note that Patient 1 (a
representative disease key) in Figure 5.1 has a feature vector of z1 = [110000] and
Patient 15 (another disease key) has a feature vector of z15 = [101100]. Each of these
is a feature vector for a separate disease. Compare this to Patient 9 whose feature
vector is z9 = [111100] and whose patient contains both diseases that are represented
by z1 and z15, which can be seen as a logical operation union between the two vectors,
notably the ”or” function in this case.
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Figure 5.1: Example of dual disease state data Zˆ (LOF and transposed)
To create a method to exploit this, a modification of binary BPFA matrix Zˆ
(the estimate of the binary matrix in Equation (3.8)) is necessary. The matrix of
single state keys is known as the M matrix, and consists of a single feature vector for
each known state, where the feature vector is meant to represent the weighted values
of each feature within a representative population with only that state. The Zˆ matrix
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then needs to be modified such that incorrect comparisons will be penalized. This
is accomplished by replacing all zero entries from the original BPFA output with a
negative one. This is known then as the matrix Y. The compete absence of a feature
is denoted by -1 and strong presence of a feature is denoted as 1. The master keys
for the single disease are then appended to Y, and the new matrix is referred to as
A. This matrix is then multiplied by the transpose of itself, and the upper-triangular
portion is kept while the lower-triangular portion is set to zero, and only the first R
rows are kept. This can be described as a new Z matrix modification and comparison
scheme between the known key data and the unknown patient data with the following
mathematical representations:
Y = g.(2Z− 1) (5.1a)
Y = [N; P] (5.1b)
M(r) =
q∑
1
pq,rN(r), r = 1 . . . R (5.1c)
A = [M; P] (5.1d)
C = UT[(hA)T (hA) + c, R] (5.1e)
Where UT[., R] keeps only the upper triangular portion of the matrices that corre-
spond to the desired R rows, R is the number of master keys (i.e., the number of
rows) in M, P is the portion of Z that contains only entries with unknown states
and no key results, N is the portion containing only the non-averaged key results, p
is the number of results in Z that correspond to each state, and g and h are scaling
factors and c is a constant that helps to account for very small number multiplication
if necessary. Additionally, q is the total number of patients in that particular state
and their individual weights are pq,r. In general, the parameter pq,r can be adjusted
to account for varying amounts of competing antibodies, in the case of immunosig-
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naturing. This can also be thought of one possible way to incorporate information
surrounding inhibition, such as competitive inhibition [101, 102]. This Z-PREDICTn
method may also be thought of as a non-normalized scaled dot product or correlation.
An alternative representation which does not average together keys for known states
may be obtained by omitting Equations (5.1c) and (5.1d) with Y = A. This is similar
to the procedure for Z-PREDICT, but may lead to a more complex representation
of the classification. However, this can help account for instances where entries are
repeated in the training data, or known keys. This difference will be discussed further
in the data simulations.
For immunosignaturing, the single states are individual diseases and the multi-
state case is when a patient immunosignature contains antibody representations in-
dicative of multiple underling diseases. As as example of this process, it is assumed
that the ground truth, or single state known keys, of patients 1-5 (breast cancer) and
11-15 (glioma) are known of Figure 5.1. Thus, in order to provide a single vector
describing each particular disease state, the entries are averaged together, creating
disease ”master keys.” This may be seen in Figure 5.2, where the first row is the
average of all of the breast cancer feature responses, and row 2 is the average of all
the glioma feature responses. They are referred to as the ground truth disease master
keys for these two disease states.
Based on results given in Figure 5.2, comparisons may now be made between
each remaining patient (rows 3-7) and the two ground truth disease keys given in
rows 1 and 2 by using Z-PREDICTn. This comparison (i.e. C) is given in Table 5.1,
when all scaling factors of Z-PREDICTn are set to 1. Note that K1 and K2 refer to
rows 1 and 2 in Figure 5.2 corresponding to breast cancer and glioma ground truth
keys respectively. Also note that R3-R7 refer to rows 3-7 of Figure 5.2 corresponding
to each of the five patients with two disease states. Note that negative numbers in the
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Figure 5.2: Dual disease state data Zˆ (LOF and transposed) and ground truth Key
resulting C matrix values show little similarity between the key and patient feature
vector of interest and positive numbers show higher similarity. From this matrix it is
possible to see that all patients (R3-R7) show positive C values with K1, indicating
that they most likely share the disease state breast cancer. The relative strengths
are given by the C values. Similarly C values of all but two patients are positive,
indicating that they also most likely have glioma. Again, the relative strengths are
given by their C values. In this example, this would result in correct classification of
all 5 patients with K1 and 3 patients with K2.
Key K1 K2 R3 R4 R5 R6 R7
Breast Cancer (K1) 2.80 0.48 3.20 2.00 1.60 1.60 3.20
Glioma (K2) 0.48 2.16 0.40 -0.80 -2.00 2.00 0.40
Table 5.1: C matrix results from Figure 5.2
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5.2.2 Beta PDF Fitting Features with BPFA for Multiple State Clustering
Similarly to how PCA may be used for dimensionality reduction in Z-PREDICTn,
beta PDF fitting (BPF) may be be used as an alternative. This method is called ZB-
PREDICTn, or Z-matrix from Beta PDF REsolution and Discovery for Immunosignature
Classification Testing up to n-states, and is used when n ≥ 2. This method uses BPF
reduction fed into BPFA for latent feature identification. The Zˆ matrix is then mod-
ified according to Equation (5.1). The C matrix then describes the relationships.
Again, with the immunosignaturing work discussed here, a state is a single disease
while multiple states is indicative of a patient having multiple diseases. However, for
other work any number of concurrent unknown underlying states does not change the
ZB-PREDICTn algorithm execution.
5.3 Multiple Disease State Clustering Results
5.3.1 Multi-Disease Dataset Descriptions
Two sets of disease datasets containing patients with single and dual disease
pathologies are also considered. The first group, labeled as multi-disease Dataset 1, or
MDD1 consists of 20 sets of key (or ground truth) immunosignatures, five from each
of the disease states: breast cancer, sarcoma, glioma, and normal. Then, ten sets of
immunosignatures were used for classification. The first five contained immunosigna-
tures corresponding to breast cancer and sarcoma, while the remaining five contained
immunosignatures corresponding to sarcoma and glioma. Immunosignatures were
placed in the following order for the analysis: 5 breast cancer, 5 breast cancer +
sarcoma, 5 sarcoma, 5 sarcoma + glioma, 5 glioma, and 5 normal. Each dual disease
immunosignature was created by taking the average of two different immunosigna-
tures, one from each disease, where median intensities of corresponding sequences
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were averaged together. The second set of data, known as multi-disease dataset 2
or MDD2, consisted of 59 sets of key immunosignatures, 20 Alzheimer’s immunosig-
natures (the first 20 entries), 20 cocci immunosignatures (entries 41 through 60), 10
myeloma immunosignatures (entries 61-70), and 9 normal immunosignatures (entries
71-79). The multi-disease immunosignatures (entries 21-40) had both Alzheimer’s
disease and myeloma.
Again, each dual disease immunosignature was created by taking the average of
two different immunosignatures, one from each disease, where the median intensities of
corresponding sequences were averaged together. Note that, where possible, different
immunosignatures were used than what are represented in the training data, but due
to small dataset availability for some diseases and the desire to show the algorithm
functioning under various conditions, some were repeated in the sarcoma, Alzheimer’s,
and myeloma groups. However, this does not greatly impact the results for the
algorithm since each repetition represents only a small portion of the training data
used in each comparison. Analysis and discussions on this averaging with relationship
to the biological model are provided in Section 7.1.
5.3.2 Type 1 and 2 Clustering Errors for Multi-disease Data
For single disease state clustering results are described using relaxed (RIC)
and strict (SIC) definitions. However, when analyzing classification results for multi-
disease datasets, it is possible to have multiple types of misclassifications where some
diseases may be classified correctly and others may not. Type I and Type II error
definitions may be used for this patient data. Statistically speaking, the Type I
error generally describes the outcome of incorrectly rejecting a null hypothesis (false
positive) [100]. In the case of immunosignaturing, a false positive occurs when a
patient has a disease but the classification fails to indicate the presence of this disease.
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The Type II error generally refers to the failure to reject a null hypothesis (false
negative) [100]. For immunosignaturing classification, this means that a patient is
classified as not having a particular disease when in fact they do have that disease
pathology.
While these same definitions can be applied to the single disease states as
well, it is more straightforward to report the cases of correct classification rather
than delineate between the different error cases. However, for dual disease state
data, it becomes necessary as some algorithm parameters may work better for certain
disease states. As such, multi disease state data will be reported by indicating the
true positive, true negative, Type I error, and Type II error for each disease state.
The true positive and true negative rates will be combined and referred to as correct
classification and the Type I and Type II error rates will be combined and referred to
as incorrect classification [100]. When using adaptive clustering, the final category,
no result, indicates that the clustering fell outside of the main results and disease
presence could not be automatically determined based on the classification results
alone without additional analysis by the user. To provide a conservative estimation
of the performance, the no result category is considered a misclassification.
5.3.3 Multiple Disease Clustering Results using PCA and BPFA
The Z-PREDICTn algorithm was evaluted with two datasets, MDD1 and
MDD2. The eigenvalue plots for MDD1 and MDD2 may be seen in Figure 5.3. The
first 11 principal components were used for MDD1, representing 93.2% of the data,
while the first 15 principal components were used for MDD2, representing 94.7% of
the data. The post BPFA results for the PCA of MDD1 and MDD2 may be seen in
Figure 5.4 and Figure 5.5. For both datasets, K = 50, and 2000 burn-in and sample
iterations each were used.
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(b) First 20 eigenvalues of MDD2 PCA.
Figure 5.3: The first 20 significant eigenvalues from each multi-disease dataset.
For MDD1, the C values are given in Table 5.2 and also plotted in Figure 5.6
for readability. Figure 5.8 and Table 5.3 correspond to MDD2. It should be noted
that row 5 (Key 5) in both datasets is simply blank and is inserted for readability
only. As one can see from Figure 5.6 and 5.8, the higher the value, the more likely
the patient is to have a particular disease. The patient entries for C are presented as
a stem plot for readability with the x-axis representing each patient and each color
coded stem in the plot representing the comparison with the known disease keys. For
each dataset, g = 10 and h = (1/100)1/2.
However, without knowing how many states, i.e. diseases, are present, it be-
comes difficult to provide a meaningful threshold of where disease significance begins
and therefore determine which diseases are present. Thus, in order to determine how
many true positive, true negative, type I error, and type II error classification results
there are, it is necessary to know the value of n where n > 1 and is the number of
states (i.e. diseases) of interest. However this is not possible without some supple-
mental patient knowledge. It is assumed that the value of n is known (n = 2 in both
cases here). While this determination may be done via several means, it is outside
this chapter’s scope; an alternative approach will be discussed in Chapter 6. Based
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Figure 5.4: BPFA results for MDD1 in Z-PREDICTn
on this assumption, the classification results in each case are summarized in Tables
5.10 and 5.11. For MDD1 this led to a true combined classification rate of 95% and
a combined error classification rate of 5%. For MDD2, this led to a combined true
classification rate of 87.5% and a combined error classification rate of 12.5%.
Also given are the un-combined results where Equations (5.1c) and (5.1d) were
removed and Y = A. All other parameters for the MCMC steps are the same. The
stem plots become cumbersome to read with so many comparisons, and thus a com-
parison matrix is given in Figures 5.7 and 5.9. For classification purposes, entries
in the top two values for each comparison were taken. The tables of comparisons
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Figure 5.5: BPFA results for MDD2 in Z-PREDICTn
for each case are given in Tables 5.5 and 5.7. This resulted in 68% combined cor-
rect classification and 32% combined error for MDD1 and 59.5% combined correct
classification and 40.5% combined error for MDD2.
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Key K1 K2 K3 K4 K5 R6 R7 R8
Breast Cancer (K1) 14.76 11.00 9.40 10.20 13.00 13.00 13.00 13.00
Sarcoma (K2) 11.00 17.00 11.40 13.00 15.00 15.00 15.00 15.00
Glioma (K3) 9.40 11.40 12.52 10.12 13.40 9.40 9.40 9.40
Normal (K4) 10.20 13.0 10.12 12.20 13.40 11.80 11.80 11.80
Key R9 R10 R11 R12 R13 R14 R15
Breast Cancer (K1) 13.00 13.40 11.00 11.00 9.00 9.00 7.00
Sarcoma (K2) 15.00 13.00 13.00 13.00 15.00 15.00 13.00
Glioma (K3) 9.40 11.40 11.40 11.40 11.80 11.80 9.80
Normal (K4) 11.80 11.40 11.40 11.40 11.00 11.00 9.00
Table 5.2: Table of MDD1 Z-PREDICTn results
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Figure 5.6: MDD1 Z-PREDICTn results using all equations of (5.1)
5.3.4 Multiple Disease State Clustering Results Using Beta PDF Fitting and BPFA
The results for MDD1 are shown in Figures 5.10. For these results, 2000 burn-
in iterations and 2000 sample iterations were used in the blocked Gibbs sampler with
K = 50 and c = 0. The result for C is shown in Table 5.8 and Figure 5.12. This
resulted in a combined correct classification of 65% and a combined error of 35%. For
MDD2 the results may be seen in Figure 5.12 where 2000 burn-in iterations and 2000
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Key K1 K2 K3 K4 K5 R6 R7 R8
Alzheimer’s (K1) 14.49 13.29 14.30 12.90 15.10 15.10 15.10 15.10
Cocci (K2) 13.29 14.76 15.80 15.20 14.00 14.00 14.00 14.00
Myelmoa (K3) 14.30 15.80 19.16 17.40 15.40 15.40 15.40 15.40
Normal (K4) 12.90 15.20 17.40 20.00 14.00 14.00 14.00 14.00
Key R9 R10 R11 R12 R13 R14 R15 R16
Alzheimer’s (K1) 12.50 12.50 14.70 14.70 14.70 14.70 14.70 14.70
Cocci (K2) 12.20 12.20 14.20 14.20 14.00 14.00 14.00 14.00
Myelmoa (K3) 13.40 13.40 15.40 15.40 15.40 15.40 15.40 15.40
Normal (K4) 12.00 12.00 14.00 14.00 14.00 14.00 14.00 14.00
Key R17 R18 R19 R20 R21 R22 R23 R24
Alzheimer’s (K1) 12.30 12.30 14.90 13.90 14.90 14.90 14.90 11.90
Cocci (K2) 12.00 12.00 16.40 14.40 16.40 16.40 14.00 12.40
Myelmoa (K3) 13.40 13.40 19.40 17.40 19.40 19.40 15.40 16.60
Normal (K4) 12.00 12.00 18.00 16.00 18.00 18.00 14.00 14.00
Table 5.3: Table of MDD2 Z-PREDICTn results
Disease True + True - Type I Type II
Breast Cancer 5/5 5/5 0/5 0/5
Sarcoma 10/10 0/0 0/0 0/10
Glioma 5/5 5/5 0/5 0/5
Normal 0/0 8/10 2/10 0/0
Table 5.4: Indication and error rates for dataset 1 after Z-PREDICTn
sample iterations with K = 50 and c = 100 were used. The results for C may be seen
in Figure 5.13 and Table 5.9. This led to a combined correct classification of 100%
and a combined error of 0%.
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Figure 5.7: MDD1 Z-PREDICTn results not using (5.1c) and (d)
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Figure 5.12: MDD1 results for ZBPREDICTn
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Disease True + True - Type I Type II
Breast Cancer 16/25 14/25 11/25 9/25
Sarcoma 35/50 0/0 0/0 15/50
Glioma 25/25 23/25 2/25 0/25
Normal 0/0 23/50 27/50 0/0
Table 5.5: MDD1 Z-PREDICTn results with (5.1c) and (d) removed
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Figure 5.8: MDD2 Z-PREDICTn results
Disease True + True - Type I Type II
Alzheimer’s 15/20 0/0 0/0 5/20
Cocci 0/0 20/20 0/20 0/0
Myeloma 20/20 0/0 0/0 0/20
Normal 0/0 15/20 5/20 0/0
Table 5.6: MDD2 Z-PREDICTn results.
Disease True + True - Type I Type II
Alzheimer’s 124/400 0/0 0/0 276/400
Cocci 0/0 292/400 108/400 0/0
Myeloma 151/200 0/0 0/0 49/200
Normal 0/0 135/180 45/180 0/0
Table 5.7: MDD2 Z-PREDICTn results with (5.1c) and (d) removed
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Figure 5.9: MDD2 Z-PREDICTn results not using (5.1c) and (d)
Key K1 K2 K3 K4 R6 R7 R8
Breast Cancer (K1) 30.00 -2.00 14.00 -14.00 -10.00 10.00 10.00
Sarcoma (K2) -2.00 20.40 -0.40 13.20 22.00 18.00 18.00
Glioma (K3) 14.00 -0.40 7.60 -6.00 -2.00 2.00 2.00
Normal (K4) -14.00 13.20 -6.00 14.00 18.00 6.00 6.00
Key R9 R10 R11 R12 R13 R14 R15
Breast Cancer (K1) 10.00 -30.00 30.00 -30.00 30.00 30.00 30.00
Sarcoma (K2) 18.00 2.00 -2.00 2.00 -2.00 -2.00 -2.00
Glioma (K3) 2.00 -14.00 14.00 -14.00 14.00 14.00 14.00
Normal (K4) 6.00 14.00 -14.00 14.00 -14.00 -14.00 -14.00
Table 5.8: ZBPREDICTn C for MDD1
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Figure 5.10: ZBPREDICTn results for MDD1
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Figure 5.11: BPFA results for MDD2
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Figure 5.13: MDD2 results for ZB-PREDICTn
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Key K1 K2 K3 K4 K5 R6 R7 R8
Alzheimer’s (K1) 35.00 27.30 38.00 4.22 42.00 42.00 42.00 42.00
Cocci (K2) 27.30 25.80 32 13.77 38.00 38.00 38.00 38.00
Myelmoa (K3) 38.00 32.00 50.00 5.55 50.00 50.00 50.00 50.00
Normal (K4) 4.22 13.77 5.55 33.33 15.55 15.55 15.55 15.55
Key R9 R10 R11 R12 R13 R14 R15 R16
Alzheimer’s (K1) 36.00 36.00 42.00 42.00 42.00 42.00 42.00 42.00
Cocci (K2) 22.00 22.00 38.00 38.00 38.00 38.00 38.00 38.00
Myelmoa (K3) 30.00 30.00 50.00 50.00 50.00 50.00 50.00 50.00
Normal (K4) -4.44 -4.44 15.55 15.55 15.55 15.55 15.55 15.55
Key R17 R18 R19 R20 R21 R22 R23 R24
Alzheimer’s (K1) 42.00 42.00 34.00 34.00 34.00 34.00 42.00 42.00
Cocci (K2) 38.00 38.00 26.00 26.00 26.00 26.00 38.00 38.00
Myelmoa (K3) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
Normal (K4) 15.55 15.55 -4.44 -4.44 -4.44 -4.44 15.55 15.55
Table 5.9: Table of MDD2 ZBPREDICTn results
Disease True + True - Type I Type II
Breast Cancer 3/5 1/5 4/5 2/5
Sarcoma 6/10 0/0 0/0 4/10
Glioma 4/5 5/5 0/5 1/5
Normal 0/0 7/10 3/10 0/0
Table 5.10: Indication and error rates for MDD1 after ZB-PREDICTn
Disease True + True - Type I Type II
Alzheimer’s 20/20 0/0 0/0 0/20
Cocci 0/0 20/20 0/20 0/0
Myeloma 20/20 0/0 0/0 0/20
Normal 0/0 20/20 0/20 0/0
Table 5.11: Indication and error rates for MDD2 after ZB-PREDICTn
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Chapter 6
H-PREDICT AND HB-PREDICT FOR MULTIPLE STATES
While Dirichlet process Gaussian mixture modeling (DP-GMM) is useful for clas-
sification in applications where there are multiple unknown states that need to be
adaptively clustered, it is not able to provide classifications in more than one group
for a single patient. One way around this issue is to use the hierarchical Dirichlet pro-
cess (HDP) in conjunction with modified beta process factor analysis (BPFA), which
simply places a prior over the initial distribution, and then executes the DP-GMM
as given in Algorithm 1. While it is possible to apply patient comparisons as inputs
to the DP-GMM, further bookkeeping is required. This is simplified with the HDP.
6.1 Hierarchical Dirichlet Process Theory
The HDP is simply an extension of the DP to include an additional DP prior
on the base measure. In the same way that the DP may be thought of as a ”Chinese
restaurant process” (CRP), the HDP may be thought of as a ”Chinese restaurant
franchise” (CRF) [103], or a non-parametric extension of linear Dirichlet allocation
[104]. The HDP is very flexible in that it allows for multiple hierarchies, which is useful
in diverse topics such as music, target tracking, and speech [105–108]. Assuming a
base distribution S, the hierarchical extension is given by:
G0 =
∞∑
m=1
βmδ(θ − θh,m) (6.1a)
Gj =
∞∑
m=1
pij,mδ(θ − θh,m) (6.1b)
θh,m ∼ S (6.1c)
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An extension to Equation (2.20, where j = 1 . . . J is the cohort number, forms a
stick-breaking representation of the HDP [109]:
G0|γh, A ∼ DP(γh, A), (6.2a)
Gj|αh, G0 ∼ DP(αh, G0), (6.2b)
β′k ∼ Beta(1, γh), k = 1, . . . ,∞, (6.2c)
βm = β
′
k
m−1∏
l=1
(1− β′l), m = 1, . . . ,∞, (6.2d)
pi
(h′)
j,k ∼ Beta(αhβm, αh(1−
m∑
k=1
(βk))), k = 1, . . . ,∞, (6.2e)
pi
(h)
j,k = pi
(h′)
j,k
m−1∏
l=1
(1− pi(h′)j,l ), m = 1, . . . ,∞ (6.2f)
The HDP equations are identical to the DP, except now a prior has been
placed on the base distribution Gj. This prior for the new base distribution is itself
a Dirichlet process with an innovation parameter γh and an underlying distribution
S. Note that αh is an innovation parameter in the DP. The subscript h in Equation
(6.2) denote the HDP dependence. The conditional distribution over which an item
(patient) may belong to a particular group (disease cluster) is given by [103, 109]:
mj,i|mj,1:i−1, αh ∼
∑
m
nj,m∑
m′ nj,m′ + αh
δ(θ − θh,m) + αh∑
m′ nj,m′ + αh
δ(θ − θnewh,m ) (6.3)
where m is a particular cluster and nj,m is the number of patients already present
in a cluster. While only two hierarchical levels are explored here, the HDP can be
extended to as many as desired depending on the problem to be solved. The blocked
Gibbs sampler algorithm with update equations for may be found in Algorithm 3.
Several papers have focused on using the HDP as a remedy to the co-clustering
problem, including [110] and [111] for haplotype reconstruction where data is unlikely
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to be pooled together. It is also investigated in [112] in a multilevel format for
human EEG monitoring and in [113] for brain fiber tract clustering. In each of these
cases, some modification of the HDP or data set model was required in order to
successfully perform the co-clustering. The immunosignaturing results determined
in Z-PREDICTn and ZB-PREDICTn lend themselves to direct implementation of
the HDP, as the data has a natural separation into groups per patient. Note that
while it is possible to apply the DP-GMM as well to the results of the Z-PREDICTn
and ZB-PREDICTn, additional bookkeeping would need to be performed in order
to first combine all patient results into a single group and then further to break
the resulting clustering into groups per patient. While the DP-GMM itself may
be relatively straightforward for cohorts with few patients present, it becomes more
tedious if the patient numbers in each cohort increases.
Although work has been done to make the implementation of the HDP more
efficient [114], implementation via a blocked Gibbs sampler is investigated here to
maintain consistency with prior immunosignaturing work performed with the DP-
GMM. In the case of immunosignaturing, two levels will be sufficient to allow for
clustering across multiple cohorts, each with their own patient groups. This is because
the first level of clustering (local) will take care of the group assignment to a particular
disease state while the second level (global) will ensure that the available clusters will
be the same across all available cohorts.
6.2 HDP Based Multiple Disease State Clustering
6.2.1 PCA Features with HDP
While successful clustering for immunosignaturing was previously demonstrated
for single diseases using PREDICT, B-PREDICT, BIO-PREDICT, and BIOB-PREDICT,
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it did not extend the clusters to disease diagnosis or multiple disease states. While
this may be sufficient if only the total number of disease states is desired, or if one is
only interested in the incidence of a new disease in a population, missing diagnoses
is impractical at a clinical level for everyday medicine. Therefore, it is desirable to
extend the previous results to include diagnosis information in addition to the ability
to extend beyond a single disease diagnosis.
The HDP is a natural addition to this work in that generally diagnosis re-
quires some sort of training data where the ground truth disease state is known.
As such, a method is devised that builds upon the Z-PREDICTn previously dis-
cussed in that the results of C are then fed into the HDP for adaptive clustering.
This method is called H-PREDICT, or HDP of PCA REsolution and Discovery for
Immunosignature Classification Testing.
6.2.2 Beta PDF Fitting Features with HDP
Similar to how PCA can be used to reduce the dimensionality in the H-
PREDICT algorithm, BPDFF can be used as an alternative. The output of ZB-
PREDICTn may be fed into the HDP. This is called HB-PREDICT, or HDP of Beta
PDF REsolution and Discovery for Immunosignature Classification Testing. This
allows the user to restrict the dimensionality to two, rather than an indeterminate
number of principal components.
6.3 HDP Clustering Results
6.3.1 Clustering Results of PCA with HDP
The H-PREDICT algorithm was tested against with datasets MDD1 and
MDD2. The MDD1 classification results corresponding to Figure 5.6 are given in
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Figure 6.1. The C matrix stem plot is also given again for reference. The classifica-
tion results are also summarized in an additional graphical representation as well. In
this depiction, each face has a number associated with it that corresponds to which
patient the data point originates from. Each group represents a cluster created in H-
PREDICT. The clusters correspond to having a state present (solid circle) while the
disease not present cluster has a slash through the cluster. Entries that are incorrectly
clustered have an asterix (*) next to their patient number. Table 6.1 summarizes the
classification results, with a combined correct classification of 75% and a combined
error rate of 12.5%. The innovation parameters were αh = γh = 3 with 5000 burn-in
iterations and 5000 sample iterations.
The MDD2 classification results corresponding to Figure 5.8 are given in Figure
6.2. The C matrix stem plot is also given again for reference. The correct combined
classification was 57.5% while the combined error rate was 20%. The innovation
parameters were αh = γh = 6 and for the blocked Gibbs sampler, 2000 burn-in
iterations and 5000 sample iterations were used.
Disease True + True - Type I Type II No Result
Breast Cancer 5/5 2/5 0/5 0/5 3/10
Sarcoma 10/10 0/0 0/0 0/10 0/10
Glioma 2/5 4/5 1/5 3/5 0/10
Normal 0/0 7/10 2/10 0/0 1/10
Table 6.1: MDD1 H-PREDICT classification summary
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(a) Stem plot of C matrix from MDD1.
1 2 3 4 5 6 7 8 9 10
15
16
17
18
19
20
21
22
23
24
Patients
Cl
as
s
 
 
Breast Cancer
Sarcoma
Glioma
Normal
(b) HDP classification results.
(c) HDP classification results.
Figure 6.1: H-PREDICT results for MDD1
Disease True + True - Type I Type II No Result
Alzheimers 10/20 0/0 0/0 9/20 1/20
Cocci 0/0 14/20 1/20 0/0 5/20
Myeloma 11/20 0/0 0/0 3/20 6/20
Normal 0/0 13/20 0/20 0/0 7/20
Table 6.2: MDD2 H-PREDICT classification summary
6.3.2 Clustering Results of Beta PDF Fitting with HDP
The HB-PREDICT classification results for MDD1 are given in Figure 6.3.
The stem plot of the C matrix is also given again for reference. The innovation
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(a) Modified Zˆ matrix from reduced MDD2.
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(b) HDP classification results.
Figure 6.2: H-PREDICT results for MDD2
parameters were αh = γh = 4 and 2000 burn-in followed by 2000 sample iterations
were used. The combined correct classification was 50% while the combined error was
25%. The HB-PREDICT MDD2 classification results are given in Figure 6.4 with
the classification results summarized in Table 6.4. The combined correct classification
was 70% while the combined error was 15%.
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(b) HDP classification results.
Figure 6.3: HB-PREDICT results for MDD1
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Disease True + True - Type I Type II No Result
Breast Cancer 2/5 0/5 1/5 2/5 5/10
Sarcoma 7/10 0/0 0/0 2/10 1/10
Glioma 4/5 5/5 0/5 1/5 0/10
Normal 0/0 2/10 5/10 0/0 3/10
Table 6.3: MDD1 HB-PREDICT classification summary
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(a) Modified Zˆ matrix from MDD2.
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(b) HDP classification results.
Figure 6.4: HB-PREDICT results for MDD2
Disease True + True - Type I Type II No Result
Alzheimers 18/20 0/0 0/0 2/20 0/20
Cocci 0/0 5/20 12/20 0/0 3/20
Myeloma 19/20 0/0 0/0 1/20 0/20
Normal 0/0 14/20 0/20 0/0 6/20
Table 6.4: MDD2 HB-PREDICT classification summary
6.4 H-PREDICT and HB-PREDICT Model Challenges
There are several difficulties with using the HDP in a classification framework
as presented in the previous sections. First, with both algorithms, a two cluster
approach is used to indicate which diseases are present. It is possible that there are
multiple clusters of interest to the user, rather than just a binary disease diagnosis.
103
Algorithm 3 Blocked Gibbs sampling for HDP using an D-dimensional co-
hort X with J individual subgroups
Input: J datasets X = {x1 . . . ,xN}, HDP innovation parameters αh and γh,
Normal-Wishart hyperparameters µN , τN , ξW , ιW , DP truncation limit M .
Output: Samples {µ(i)m ,Σ(i)m , c0(i),w(i)0,J}Li=1
Repeat for i = 1, 2, . . . , Gibbs iterations:
1. Update for θ(i)m = {µ(i)m ,Σ−1(i)m } ∼ p (µm,Σ−1m |c(i−1),X), m = 1, . . . ,M .
(a) Let Xm = {xn : c(i−1)n = m} and Nm = |Xm|, for m = 1, . . . ,M .
(b) For all clusters, m = 1, . . . ,M , compute,
µxm =
1
Nm
∑
n:c
(i−1)
n =m
xn
Σxm =
1
Nm
∑
n:c
(i−1)
n =m
(xm − µxm)2
µ˜N ,m =
τN µ˜N +Nmµxm
τN +Nm
,
τ˜N ,m = τN +Nm ,
ι˜W,m = ιW + Σxm +
τN Nm
τN +Nm
(m− µxm) (m− µxm)T ,
ξ˜W,m = ξW +Nm .
(c) Draw samples for Σ−1(i)m from the Wishart distribution,
W (Σ−1m ; ι˜W,m, ξ˜W,m), for m = 1, . . . ,M .
(d) Finally draw samples for µ
(i)
m from the Normal distribution,
N (µm; µ˜N ,m, Σ
(i)
m
τ˜N ,m
), for m = 1, . . . ,M .
2. Do the global update.
(a) Draw samples βg ∼ Beta
(
1 +N∗m, γh +
∑M
m′=m+1N
∗
m′
)
,
where N∗m , |{n : c(i)n = m}|, m = 1, . . . ,M .
(b) Update for w
(i)
m ∼ p (w0m|c(i)), m = 1, . . . ,M .
Finally evaluate w
(0,i)
m = βm
∏m−1
g=1 (1− βg), m = 1, . . . ,M .
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Algorithm 3 Continued
3) Do the local updates for all J groups
a) Let qjm,n , w
j,(i−1)
m N (xjn;µ(i)m ,Σ(i)m ), m = 1, . . . ,M and n =
1, . . . , N .
b) Normalize qj,′m,n =
qjm,n∑M
m=1 q
j
m,n
,m = 1, . . . ,M and n = 1, . . . , N .
c) Update for c
j,(i)
n ∼ p (cjn|µ(i),Σ−1(i),w(i−1),X), n = 1, . . . , N . Draw
samples for c
j,(i)
n ∼ ∑Mm=1 qj,′m,nδ(cjn,m), n = 1, . . . , N . Note that
c = c1:J .
d) Draw samples βjl ∼ Beta
(
αhw
j,(i−1) +N∗m, αh(1− wj,(i−1))
)
, where
N∗m , |{n : cj,(i)n = m}|, m = 1, . . . ,M .
e) Update for w
j,(i)
m ∼ p (wjm|cj,(i)), m = 1, . . . ,M . Finally evaluate
w
j,(i)
m = β
j
l
∏m−1
l=1 (1− βl), m = 1, . . . ,M .
As such, additional disease or patient information would be required in order to
interpret additional clusters. Further, when ”no result” groups are created, additional
information may be required in order to determine patient diagnosis. Fortunately,
because this method is executed in a multidimensional embodiment, it is possible
to add other patient features or data points as a multidimensional patient vector,
and classify hierarchically based on that information as well. Additionally, with
every additional layer of hierarchy, computational complexity increases, leading to
increased execution time for convergence in the blocked Gibbs sampler.
105
Chapter 7
COMPARISON OF PROPOSED CLUSTERING ALGORITHMS
Now that various methods have been proposed and applied to various datasets, the
results discussion is presented. In the case of the single disease methods, this includes
comparison with a known method that performs well for immunosignaturing anal-
ysis. For the multi-disease methods, no alternative analysis has been presented for
immunosignaturing, and alternate Bayesian non-parametrics are not suitable without
further modification. Each method’s link to the biological model is discussed in order
to provide a background and reasoning for some of the model selection.
7.1 Method relationships to the biologic model
A variety of methods have been presented, each with their own benefits and
tradeoffs for immunosignaturing analysis. Before these results are discussed in depth,
it is helpful to have an understanding of the biological models that they each repre-
sent. As with most models, these seek to represent the natural phenomena (in this
case disease pathology) in a simplified way for better understanding. In terms of
immunosignaturing arrays, it has been shown that the presence of a disease state will
be indicated by the binding of antibodies specific to that particular pathology to the
random, but known, peptide sequences present on the glass immunosignaturing slide.
Particular antibodies will bind with varying affinities to the peptide sequences present
in the spot locations based on chemical interactions [15]. As such, the fluorescence
combinations will be indicative of various disease states [7–13].
In the case of PREDICT (PCA REsolution with DP-GMM for Immunosigna-
ture Classification Testing) and B-PREDICT (Beta PDF REsolution with DP-GMM
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for Immunosignature Classification Testing), these combinations are reduced to ei-
ther distribution parameters that represent the binding behavior (B-PREDICT) or
principal component analysis (PCA) components used to eliminate small binding
contributions (PREDICT), and then the Dirichlet process Gaussian mixture model
(DP-GMM) is used to classify patients based on these parameters. In the case of
PREDICT, the PCA components themselves are representative of combinations of
peptide binding results, and thereby are the high intensity value spots of interest.
Since these are discernible by data inspection, these are considered visible processes
to the viewer. While there is still useful information to be gleaned from the peptides
that are not high intensity, because the peptide array is fixed, if one knows which
peptides are considered high intensity, then it is also known which are not considered
high intensity.
It should also be noted that the threshold for significant peptide combinations
is determined by the eigenvalue analysis, which is user determined. Thus, the user
is indirectly setting a threshold for intensity significance. For B-PREDICT rather
than directly or indirectly imposing a significance threshold for the intensity mea-
surements, a more holistic view is taken to describe the distribution of all the peptide
intensity measurements. This has some advantages in that no peptides are discarded
in the analysis, aside from those having no or negative measurements from the ac-
tual equipment, which are discarded in in any case. Interestingly, the PCA and beta
PDF fitting (BPF) dimensionality reductions are complementary, and datasets may
do better with one or the other based on their antibody characteristics. For example,
it is possible that peptides of interest will be discarded during the eigenvalue analysis,
especially if only a few small pathological changes are present. These changes may be
lost due to the imposed thresholding, and important disease information subtleties
will be lost. Conversely, the BPF version will miss multi-modal distributions and
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their subtle changes, and may not have the resolution to distinguish distributions
that are very similar, but whose underlying peptide combinations are very different.
As such, it is important to retain both dimensionally reduction techniques and allow
the user to apply the case more suited to their analysis, even though this may require
additional data or user consideration.
In the case of Φ-PREDICT (Φ PCA REsolution and Discovery for Immunosig-
nature Classification Testing), Z-PREDICT (Z-matrix from PCA REsolution and
Discovery for Immunosignature Classification Testing), and ZB-PREDICT (Z-matrix
from Beta PDF REsolution andDiscovery for Immunosignature Classification Test-
ing), the beta process factor analysis (BPFA) is performed on the BPF or PCA
down-selected dataset (i.e. encoding of the discernible feature space). In this way,
latent features are discovered for each algorithm. As previously discussed, prefer-
ential antibody binding leads to high intensity spot combinations, which are then
summarized through BPF or PCA and then classified to indicate disease pathology.
When the BPFA is introduced, it creates an additional step in the process where by
the disease pathology is now linked to K latent features, and those K latent features
are linked both to patient and to the high intensity peptides of interest. As such, the
classification is performed on the latent features themselves, rather than the metrics
that are directly related to a biological phenomena. It should also be noted that while
the BPFA can show the latent feature relationships, it does not identify the latent
features themselves. In the case of immunosignaturing, this means that the algo-
rithm does not provide a link to a biological phenomena for the K features. However,
this fact itself does not prevent clustering, as in BIO-PREDICT (BPFA Including
prOcessing with PCA REsolution and DP-GMM for Immunosignature Classification
Testing) or BIOB-PREDICT (BPFA Including prOcessing with Beta PDF REsolu-
tion with DP-GMM for Immunosignature Classification Testing), or further analysis,
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such as in the case where peptide analysis is studied. Peptide analysis was not the
focus of this work, but as each of these methods was able to identify patients with sim-
ilar feature profiles, the BPFA may also be used to study peptides of significance for
each disease. It is interesting to note that in order to toggle between methods that
are geared towards examining disease diagnosis and those that are geared towards
peptide analysis, all one needs to do is transpose the initial data matrix X containing
the median peptide intensities, and then execute the proper method. This will simi-
larly change the dimensionality from peptides (in the case where disease diagnosis is
the preferred path) to patients (in the case where peptide analysis is desired). These
methods allow for complementary analysis to occur when using the same dataset, and
represent diverse options in the toolbox for those studying immunosignaturing.
When considering multiple diseases, the same biological ties still exist, but
they are simply expanded to include a wider range of disease possibilities. In Z-
PREDICTn (Z-matrix from PCA REsolution and Discovery for Immunosignature
Classification Testing up to n-states) and ZB-PREDICTn (Z-matrix from Beta PDF
REsolution and Discovery for Immunosignature Classification Testing up to n-states),
the subsequent Z matrix analyses are done simply to compare known disease profiles
of the patients. Thus, the same latent K features are now known for some diseases
(although they are still not related to a known biological phenomena), and these can
be compared to the K feature profiles for patients with unknown disease pathologies.
While these methods are demonstrated in the presence of multiple diseases for each
patient, they are still valid in single disease settings, especially when there is a desire
to understand disease relationships. It is possible that disease pathogens that share
biological similarities will share very similar pathology responses. One example of
this would be the relationship of small pox to that of cow pox. Although these are
separate pathogens that affect different species, their relationships to one another have
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allowed for similar antibody responses from the human immune system [42]. Thus,
if diseases share similar combinations of high intensity spots, it may be possible that
they share similar immunosignaturing intensity distribution parameters or similar
high intensity peptide combinations. As such, it is possible that they will share similar
latent features, thereby leading to similar Z matrices, and similar clustering results.
Thus, these methods may be useful to show disease similarities, such as structure or
phylogenic relationships. Further work may be done in this area to better explore
disease relationships.
It is also useful to note that in Φ-PREDICT, Z-PREDICT, ZB-PREDICT,
BIO-PREDICT, BIOB-PREDICT, Z-PREDICTn, and ZB-PREDICTn, the unweighted
BPFA algorithm is used. Though more restrictive than the weighted case, this was
thought to be the simplest case from the biological model standpoint in that each
estimated matrix could be used to describe a particular biological relationship. For
example, in Z-PREDICT, the Z matrix indicates the relationship between latent fea-
tures and patients while the Φ matrix represents the relationship between the latent
features and prominent peptide intensity combinations. The introduction of a matrix
of weights would require further biological understanding for which no data was taken
for immunosignaturing. However, this leads to some assumptions with the biological
model being represented, especially in the case of multiple diseases. It is possible
that antibodies may bind to multiple peptide spots and that there may be some com-
petition between antibodies for binding sites [19]. The biological model in this case
assumes that this is not a dominant affect. It is possible that the introduction of
the weight matrix in the BPFA may indicate which peptide combinations are at odds
with one another when binding (outside the scope of this work).
Thus, as the relationships become more complicated, an adaptive classifica-
tion scheme is useful. While it is possible to use the DP-GMM directly on the
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Z-PREDICTn or ZB-PREDICTn results, this would lead to additional bookkeeping.
As such, the HDP is a useful tool yielding the H-PREDICT (HDP of PCA REsolution
and Discovery for Immunosignature Classification Testing) and HB-PREDICT (HDP
of Beta PDF REsolution and Discovery for Immunosignature Classification Testing)
algorithms. In a clinical setting a medical professional is only interested in whether
or not a patient has a particular disease, hence the desire for only two clustering re-
sults (the patient has the disease or the patient does not have the disease). However,
in the case where disease relationships need to be understood, several sub-groups or
additional clusters may be useful. These could correspond to further biological states
such as having previously had the disease, or perhaps instances where the patient is
somewhere in the disease response continuum, as in the are of time course data.
Given these assumptions and limitations to the model, further refinement is
possible. The inclusion of the weight matrix along with some additional biologic
information on the binding effects of the antibodies themselves could lead to a more
refined model, especially where further analysis of the peptides themselves is desired.
In the case of patient classification, additional clusters could be identified and tied to
other biological states in patient pathology, for example those corresponding to time
effects in disease states. Given the basis for these models, further discussion of each
method will be undertaken next.
7.2 Single State Comparison to Naive Bayes Classification
For comparison purposes in the area of single disease results, the same single
data sets were analyzed using the naive Bayes approach indicated in [7]. This method
was selected for comparison because it represented the highest performing method in-
dicated amongst the presented algorithms. Peptides were selected using the ANOVA
method and at the ∼ 200 peptide significance level, though due to p-value thresh-
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olding dataset 1 only had 198 peptides and dataset 2 only had 197 peptides. Two
methods were selected to create training sets for this method. Due to limited data
availability for some of the diseases, the first training set was constructed as a circu-
lar moving average [115] (CMA) of four of the five immunosignaturing microarrays
for each disease. This can also be thought of as leave one out averaging where for
each entry in the training set for each disease state, the average of all but one (the
one currently being classified) of the microarray median intensity data is used. This
creates a conservative comparison by which to compare the other single disease state
immunosignaturing results, as not much variation exists between the training set and
actual datasets for the naive Bayes implementation which theoretically will provide
good classification results. The results for each dataset are given in Figure 7.1. The
resulting confusion matrix for each dataset is given in Tables 7.1 and 7.2. The second
training set was contrived by using leave one out cross validation (LOOCV) [7, 116–
118]. These results are also given in Figure 7.1, and the corresponding confusion
matrices are given in Tables 7.3 and 7.4. Note that for these cases the SIC and RIC
criteria are differently described. In this case, CMA is considered SIC while the RIC
is considered the LOOCV case. Dataset 1 had a correct classification rate of 80% and
40% while dataset 2 had a correct classification rate of 84% and 84% for the CMA
and LOOCV methods respectively. The better of the two classification results for
each dataset will be used for comparison purposes.
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(a) Dataset 1 with CMA.
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(b) Dataset 2 with CMA.
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(c) Dataset 1 with LOOCV.
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(d) Dataset 2 with LOOCV.
Figure 7.1: Naive Bayes classification of single disease datasets.
Class C1 C2 C3 C4 C5 C6
C1 5/5 0/5 0/5 0/5 0/5 0/5
C2 0/5 4/5 0/5 1/5 0/5 0/5
C3 1/5 0/5 3/5 1/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 0/5 1/5
C5 0/5 0/5 0/5 0/5 3/5 2/5
C6 0/5 0/5 0/5 0/5 0/5 5/5
Table 7.1: Confusion matrix for
Dataset 1 using naive Bayes with
CMA.
Class C1 C2 C3 C4 C5
C1 5/5 0/5 0/5 0/5 0/5
C2 0/5 2/5 0/5 0/5 3/5
C3 0/5 0/5 5/5 0/5 0/5
C4 0/5 0/5 0/5 4/5 1/5
C5 0/5 0/5 0/5 0/5 5/5
Table 7.2: Confusion matrix for
Dataset 2 using naive Bayes and CMA.
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Class C1 C2 C3 C4 C5 C6
C1 3/5 0/5 2/5 0/5 0/5 0/5
C2 1/5 1/5 1/5 2/5 0/5 0/5
C3 2/5 0/5 2/5 1/5 0/5 0/5
C4 0/5 2/5 0/5 2/5 1/5 0/5
C5 0/5 0/5 1/5 1/5 2/5 1/5
C6 0/5 0/5 0/5 0/5 3/5 2/5
Table 7.3: Confusion matrix for
Dataset 1 using naive Bayes and
LOOCV.
Class C1 C2 C3 C4 C5
C1 4/5 1/5 0/5 0/5 0/5
C2 1/5 4/5 0/5 0/5 0/5
C3 0/5 1/5 4/5 0/5 0/5
C4 0/5 1/5 0/5 4/5 0/5
C5 0/5 0/5 0/5 0/5 5/5
Table 7.4: Confusion matrix for
Dataset 2 using naive Bayes and
LOOCV.
7.3 Algorithm Robustness and Sensitivity
There are several steps in the algorithm that require user input for success-
ful execution. The first user interaction happens with the PCA visible feature and
dimensionality reduction step. In this step, eigenvalue truncation happens at some
user specified point thereby creating the threshold for significance. If the truncation
limit is to too low, not enough data will be selected for good feature resolution. If the
truncation limit is too high, little performance gain may be achieved while drastically
increasing the amount of data required to analyze. As such, data is truncated at
greater than 90% to help capture the majority of underlying variance in the datasets.
The user must exercise some discretion in selecting the truncation limit, and some
iteration may be necessary to show that sufficient information has been included.
An alternative approach would be to include a performance metric that is automati-
cally calculated and then approach the truncation limit selection like an optimization
problem. However, this expansion is outside the scope of this work.
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The next place user interaction may be required is in the execution of the DP-
GMM. The user must specify either the total number of clusters (M) or must specify
an error threshold, in addition to the innovation parameter α and base parameters.
These selections drive the clustering behavior of the algorithm. If one selects values
that are very restrictive, it is possible to achieve a new cluster for every single data
point, while values that are not sufficiently restrictive may lead to only a single cluster
being identified. While this may seem like a highly variable process, some solutions
will better describe the data.
This analysis is performed by simply inspecting the data and clustering com-
parison. Note that this comparison does not require that one know the true underlying
state in order to determine if the clustering solution is a good match. This simply
requires inspecting the created clusters and determining if the clusters accurately re-
flect the feature space behavior. An example of the clustering results overlaid in the
feature space may be seen in Figure 7.2. As one can see from this image, the estimated
Gaussian distributions roughly match with the data. When considering the cluster-
ing of the latent BPFA feature space, this is demonstrated in the heuristic clustering
methods presented in the Z-PREDICT and ZB-PREDICT algorithms. While it may
be argued that such inspection violates the theoretical purposes behind using these
adaptive methods, the practical application of such algorithms does not happen in a
vacuum. Data need not be inspected or analyzed by human intervention, but could
be done via some broader algorithm analysis. For example, one could compute the
number of points in each cluster and determine the naturing of the clustering result.
Another place in which the user interaction will be required is the selection
of parameters for the BPFA. Similar to the DP-GMM, parameters may be set so
restrictively that all features are shared or that no features are shared. However,
with the BPFA it was observed that when moving away from optimal solutions the
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(b) Classification results.
Figure 7.2: B-PREDICT results for Dataset 2.
Z matrix becomes highly variable. This can result in all features being zero or one
regardless of the K truncation value chosen. This simply means that the parameters
selected do not allow for good estimation given the dataset. A secondary metric that
may be used to determine if adequate parameters have been selected is to look at the
ordered values of pi values and determine if only a few significant values are present
while the others are close to zero. However, once the user is in the approximate
vicinity of optimal parameters some variation can be seen in the Z matrix results.
In this case, one cannot directly inspect the feature space to determine if parameter
selection is adequate due to the fact that this is a latent feature space that is not
observable to the user. As such, one must pay careful attention to the Z matrix. In
the case of the data examined here, very little variation was seen in features, with only
a few appearing or disappearing when the initial parameters were changed. However,
this does not mean that this will be the case for all data. An example of feature space
comparisons is given in Figure 7.3. Note that when the features vary by an order of
magnitude, the determined feature space does not drastically change. This can also
be seen by examining the unrounded results for the same parameters. However, when
the parameters are very drastically changed, the ability to resolve individual features
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is lost. A large number of small valued features may be seen throughout the Zˆ matrix.
Note that other than the a and b parameters, all other features were held constant:
K = 50, and the number of burn-in and sample iterations were 2000. One way to
overcome the issue of not being able to observe the latent feature space directly would
be to include data whose ground state is known, such as in the multi-disease state
option, and optimize for the known data. This provides the opportunity to narrow
the feature space while simultaneously examining the performance. This may also be
done automatically through an optimization problem where known data performance
is monitored and set up as an optimization problem. This is outside the scope of this
work as it was not immediately necessary or heuristically performed by the user, such
as in the case of Z-PREDICTn and ZB-PREDICTn.
Finally, it should be noted that since most of the model estimation for all
algorithms are MCMC based algorithms, slightly different results may be obtained
by running the algorithms multiple times with exactly the same parameters. This is
due to the fact that different chains will iterate towards slightly different estimations.
One way to overcome this issue is to run the same parameters with multiple chains and
then analyze each of the results using some success criteria, such as fit to the feature
space. This is why for all simulations performed in this dissertation, each MCMC
step was run a minimum of three times and then the best solution was selected.
7.4 Multi-State Comparison to the Single State Limits
In order to understand the multi-state data combined performance results, it is
helpful to compare other algorithms of similar functionality. However, for immunosig-
naturing data of this type, no prior work was available for multi-state analysis. As
such, we consider the improvement over the theoretical best performance that can be
achieved in the case of single state analysis. However, if the multi-state algorithms
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Figure 7.3: ZB-PREDICT binary matrix results for various parameters
perform worse than if a single state version were used in its place, no improvement
can be claimed. We define two terms to describe the theoretical best performance
limit for multi-state analysis when analyzed with single-state methods.
The first term is the ”Single State Upper Bound,” or SSUB, which is simply
the highest possible true positive and true negative results that could be achieved
for n underlying states when analyzed with a single state method, since only one
state may be identified in the single state methods. As such, the ”Single State Lower
Bound,” or SSLB, is then defined as the lowest type I and type II error that could
be achieved given the SSUB. The SSUB and SSLB refer to the combined true posi-
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tive/true negative or combined type I/type II error percentages respectively. To find
these values, it is first necessary to examine the true positive, true negative, type I and
type II error values, as can be seen in the first four columns of Table 7.5, represent-
ing the limits when this is performed over Ψ key comparisons. This can give more
information than the combined SSLB and SSUB values in that certain algorithms
may be more adept at achieving good results in one of the categories at the expense
of the others. For example, an algorithm may achieve good true positive or negative
results but at the expense of some of the error terms. The combined correct results,
or SSUB, and the combined error, or SSLB, over all comparisons are then given in the
last two columns. Note that this arrangement is true under the assumption that all
N datasets have n underlying states. It should also be noted that, unlike previously
discussed multi-state algorithms, the ”no result” category is not factored in due to
the underlying assumption of perfect clustering, but only single state identification.
In reality, perfect clustering is not likely given the methods discussed previously.
True + True - Type I Type II SSUB SSLB
N
nN
NΨ−nN
NΨ−nN
0
nΨ−nN
nN−N
nN
1+Ψ−n
Ψ
n−1
Ψ
Table 7.5: Single state limits
7.5 Multi-Disease Dataset Training Set Comparison
While the single state clustering methods do not require a comparison dataset
to perform the clustering, training datasets would be required in order to complete
the classification. While this would be relatively straightforward by including im-
munosignature data for known diseases and running it in parallel through the various
single state algorithms, it would still create a semi-supervised environment. Similarly,
the multi-disease methods require known immunosignature data in order to complete
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the clustering. However, in this case the data is an integral part of the algorithm,
though it is not necessarily used in the adaptive portions for model estimation. As
such, some discussion is useful in terms of the performance seen in previous results
in order to understand the impact to the method.
Consider MDD1; previous results have a low number of available datasets
for several of the diseases, and thus removing any one immunosignature datapoint
may have critical impact on the performance. For instance, the results for the C
matrix are given in Figure 7.4(a). There is some redundancy in the data points
due to the low number of available datasets (the sarcoma and a single entry in the
glioma key datasets). This represents a full averaging of all available datasets in
the key comparison data. In order to see this impact, the averaging step, Equation
(5.1c), is removed from the Z-PREDICTn algorithm and all datasets are compared
to every key. This result in shown in Figure 7.4(b). While this provides a more
complete picture of the interactions, the thresholding becomes more difficult in that
many of the data points overlap, where as previously only the top results in each case
need to be considered. In this figure, there are quite a few top results present. As
such, the top two values for each patient were considered. Given this complexity, we
want to unite the two approaches so that analysis is simplified. As such, the CMA
approach discussed in section 7.2 is used here these results are represented in Figure
7.4(c). There is not much difference between this and Figure 7.4(a), meaning the full
averaging approach is nearly equivalent to the CMA approach. The results for these
three training set methods are presented in Table 7.6. For the full averaging training
data, the combined correct classification was 95% with a total combined error of 5%.
For the training data with no averaging, the combined correct classification was 68%
with a total combined error of 32%. For the CMA training data the combined correct
classification was 92.5% with a total combined error of 7.5%.
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Figure 7.4: C results comparisons for various training sets
Disease True + True - Type I Type II
Full Averaging 20/20 18/20 2/20 0/20
No Averaging 76/100 60/100 40/100 24/100
CMA 19/20 18/20 2/20 1/20
Table 7.6: Indication and error rates for dataset 1 after Z-PREDICTn
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7.6 Results summary table
Tables providing the classification results for all methods are given in Tables
7.7 and 7.8. Note that combined correct classification and combined error rates are
given for the multi-disease datasets.
Method
Dataset 1 Dataset 2
SIC RIC SIC RIC
PREDICT 60% 60% 64% 64%
B-PREDICT 70% 76.7% 64% 64%
Z-PREDICT 60% 73.3% 88% 88%
ZB-PREDICT 83.3% 83.3% 76% 76%
Φ-PREDICT 43.3% 53.3% 60% 68%
BIO-PREDICT 66.7% 66.7% 88% 88%
BIOB-PREDICT 83.3% 83.3% 76% 76%
Naive Bayes 80% 40% 84% 84%
Table 7.7: Single state algorithm clustering performance comparison.
Method
MDD1 MDD2
Correct Error Correct Error
Z-PREDICTn 95% 5% 87.5% 12.5%
ZB-PREDICTn 65% 35% 100% 0%
H-PREDICT 75% 12.5% 57.5% 20%
HB-PREDICT 50% 25% 70% 15%
Single State Limits 75% 25% 75% 25%
Table 7.8: Multi-state algorithm classification performance comparison.
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7.7 Method results discussion
Considering Table 7.7, one can see that no method provides 100% correct
classification in all datasets. As such, there are tradeoffs for each method. First
considering the naive Bayes approach, this method requires a training set regardless
of whether the CMA or LOOCV approaches are selected. The LOOCV approach
as provided in literature was expanded to a CMA approach in order to determine
if there were more optimal training sets that could provide improved performance
understanding. The CMA approach performed as well or better than the LOOCV
approach for both datasets. Both these methods have the benefit of providing di-
agnosis information using a straightforward approach with fairly low computational
complexity. However, the inherent tradeoff with these approaches are that they are
supervised and good for single classification assignments. If a novel pathogen response
is detected, it will automatically attempt to bin it into one of the known disease states
present in the training data.
While it may be possible to contrive methods that expand on the naive Bayes
approach in order to compensate for this, such as thresholding the resulting compar-
ison values in the algorithm, multiple novel biothreats would all be lumped together.
Additionally, since a training set is required, the clustering is highly dependent on
the use of a good training set. For some of the data analyzed, only a limited number
of immunosignatures were available. Furthermore, there is concern that the training
data will need to take into account not only all known diseases for classification, but
also be representative of a variety of pathological responses for one particular disease
state. It is conceivable that even within a patient population that the manifesta-
tions of a single disease may take on a variety of immune responses, and accurately
capturing these in the training data would be required for accurate classification.
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This then leads to the necessity for unsupervised methods that are capable of
detecting varied immunological responses without the need for comprehensive train-
ing data. These methods are represented by the remaining methods detailed in Table
7.7. As one can see from these results, no method resulted in perfect clustering
and that some results may be disease state dependent. Additionally, some methods
performed better, as well as, or worse than the CMA and LOOCV naive Bayes em-
bodiments. However, in general, as the methods grow in complexity, their clustering
results improve.
When considering the PREDICT and B-PREDICT methods, one can see that
there may be a slight improvement when using the B-PREDICT approach. However,
for reasons explained in section 7.1, it is important to retain both methods to have a
variety of approaches for the corresponding variety of biological responses that may
be received. Furthermore, these two methods provide a great way to downselect
the data dimensionally from ∼ 10000 unique sequences, to some lower number of
significant data points, though it should be cautioned that the term ”significant”
may also be subjective. It is also worth noting that though the results vary from
60% to ∼76%, these two methods represent the lowest computational requirements
for the adaptive learning algorithms presented here. Thus, it may be possible that
if the immunosignaturing approach was downsized for applications where on-the-
fly analysis was required, such as battlefield or rural settings where sophisticated
equipment is scarce and diagnosis time is critical, this may be an acceptable first
step in helping diagnose pathogens. Additionally, it may be possible to improve
this method by incorporating additional patient data, such as symptoms or time
of infection, to extend the multidimensional data arrays prior to input into the DP-
GMM. As such, these methods may still have important applications in non-lab based
settings. However, we want to improve upon these methods for better clustering.
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This then leads to the Φ-PREDICT, Z-PREDICT, and ZB-PREDICT meth-
ods, whose common adaptive step is the BPFA. From the results presented in Table
7.7, Φ-PREDICT performs the worst out of these three methods. This could be due
to the fact that while the latent feature determination is adaptive, the subsequent
clustering analysis is not and requires additional subjective user input for both the
quantization levels as well as the definitions of SIC and RIC. Because these can be
quite varied, and because a fairly conservative approach was discussed in section 3.6.3,
somewhat low correct clustering results are presented here. However, this does not
mean that this method cannot be expanded or still useful in a lab based setting. This
method provides the unique ability to not just show feature presence in a binary sense
(as with Zˆ based methods), but to show feature presence linked to quantity. This
can help to detect more subtle changes in the antibody profiles rather than simply
a binary on/off state analysis. It should also be noted that it may be possible to
improve this classification by the application of the DP-GMM rather than a user
specified quantization scheme. Additionally, this method employed PCA and did not
delve into a similar method that would employ the BPF dimensionality reduction
scheme. These were not pursued due to the increased performance gains found when
using the Z-PREDICT and ZB-PREDICT methods, which inherently required less
user interaction.
In both Z-PREDICT and ZB-PREDICT, the BPFA is used to determine un-
derlying features that are not directly discernible to the user. However, it does this
by focusing on the binary presence summary indicated by the Zˆ matrix. This pro-
duces immense gains over the Φ-PREDICT method and was as good or better than
either the PREDICT or B-PREDICT methods, and in some cases the naive Bayes
approaches. While these are more computationally intensive, they do provide addi-
tional insight into the binding behavior for the various disease states, which may be
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reflected in the performance of each algorithm on the different disease datasets. This
again highlights the need to have the adaptive approach be flexible enough to capture
varied pathology responses while still providing good clustering. The main issue with
these three methods, however, is the fact that the clustering itself is not adaptive.
While this is inherently not a problem, as the datasets grow in both the number of
patients and possibly even the number of peptides analyzed, there is a need to con-
stantly adapt the output to the changing parameters. As such, adaptive clustering
expansions of the Z-PREDICT and ZB-PREDICT methods were proposed.
These expansions are called the BIO-PREDICT and BIOB-PREDICT meth-
ods, and their results are comparable to those achieved in Z-PREDICT and ZB-
PREDICT, as seen in Table 7.7. This helps to link together the adaptive determina-
tion of underlying or latent features with clustering based on those features. What is
important to note is that this requires an expanded view of the BPFA in that single
features are not indicative of single disease states. Rather, multi-feature combinations
are indicative of disease states. As such, the feature spaces are treated as multidi-
mensional spaces for input into the DP-GMM. The downside is that now two MCMC
techniques are required, and the computational complexity of execution increases.
It is useful to note that the maximum amount of clusters that may be repre-
sented by K features from the BPFA is 2K , meaning that even if too few features
are selected for BPFA analysis or if the values of a and b are set to cause a high
amount of feature combination, it may still be possible to obtain resolution between
disease states. However, while the DP-GMM only needs to estimate a single weight
for each class as defined by M , a precision, and a mean value for each data point (per
Algorithm 1), the number of items to estimate for each of the patients in the BPFA
is very dependent on the value selected for K. As such, DK values are estimated for
the Φ matrix, KN values are estimated for the Z matrix, and a single value for σ2n
128
for the error. Thus, as the number of features specified for the BPFA increases, the
number of estimate computations greatly increases.
Furthermore, it is important to have sufficient data present such that the BPFA
achieves good resolution. This can be improved and even expedited by good selection
of the priors. While the same is true for the DP-GMM, the rate of estimated values
increases at a slower rate defined by the truncation factor M . However, these two
methods performed comparably to the naive Bayes approaches, but did not require
training sets in order to perform the clustering. It is worth noting as well that there
are methods in literature that exist to combine the DP-GMM and BPFA, but had
this approach been used first, the view of multiple underlying features corresponding
to a single disease may have been lost. While this may not have been critical when
clustering the immunosignatures, it is critical if one ever has the desire to link the
features back to the biological effects happening amongst the peptide groups. It is
also critical if there is a desire to reward or penalize certain behavior based on the
tolerance for error in the end use application. However, the combination of these two
methods may be possible improvements for future work.
Each of the methods described previously (naive Bayes, PREDICT, B-PREDICT,
Φ-PREDICT, Z-PREDICT, ZB-PREDICT, BIO-PREDICT, and BIOB-PREDICT),
have a common underlying assumption in their execution. This assumption is that
all patients have only a single disease state at a given time, which may be too re-
strictive in practice, especially in a clinical setting. Furthermore, with the exception
of naive Bayes, these methods do not provide the critical disease diagnosis link that
is desired (i.e. they do not inherently perform classification without the introduction
of known disease state data). While it is possible that known immunosignatures may
be included to help identify each cluster (and even possibly eliminate the need for
separate SIC and RIC criteria), this was not undertaken due to the recognized re-
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strictiveness of the single disease state requirement. However, this would not impact
the detection of a novel biothreat in a population, for which immunosignatures may
not be available.
In order to expand upon the single disease restriction, but to also retain the
adaptive learning elements of these methods, four new method were proposed. These
include Z-PREDICTn, ZB-PREDICTn, H-PREDICT, and HB-PREDICT. The re-
sults for these multi-disease embodiments maybe be seen in Table 7.8. The Z-
PREDICTn and ZB-PREDICTn are direct expansions of the Z-PREDICT and ZB-
PREDICT methods previously discussed, in that they now incorporate known im-
munosignatures for which to compare patient data. This requires further expansion
of the BPFA results to now include the possibility that the feature combinations are
indicative of single disease states, and also that combinations of these combinations
may be indicative of multiple underlying states. This is yet another reason why the
direct linkage between the BPFA and other adaptive classification methods may be
difficult to implement for immunosignaturing. These types of relationships may have
been missed and thus resulted in single disease classification had they been combined
directly or had the Z-PREDICT or ZB-PREDICT methods been used blindly.
It should also be noted that the Z-PREDICTn and ZB-PREDICTn methods
still improve upon the CMA and LOOCV naive Bayes methods in that multiple
diseases may now be identified. As one can see, these methods provide fairly good
classification results, but at the expense of needing additional information in order
to identify present diseases, notably that one must know the number of underlying
diseases. This could also be considered a thresholding problem where the user may
specify a level of significance in order to identify the present diseases. It may also
be possible to modify the naive Bayes approach to perform in a similar manner
by avoiding the final group assignment in the algorithm, and simply plotting the
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comparisons made to the training data and then imposing the user specified threshold.
However, this was not pursued due to the user specified threshold requirement.
Two additional methods were proposed: H-PREDICT and HB-PREDICT.
These methods seek to adaptively classify the values achieved when comparing the
known key immunosignatures with those of unknown patients. Due to the variation
seen in the comparison values for the various patients, it is possible that the classifi-
cation results will be lower than that for Z-PREDICTn and ZB-PREDICTn, which
is reflected in Table 7.8. Note that it would be possible to apply the DP-GMM to
the results of the Z-PREDICTn and ZB-PREDICTn algorithms, but not directly. In
order for that occur, patients must not be seen as a multidimensional dataset, and
all data must be combined into a single dimension disease set. While this is not
impossible, it does require additional bookkeeping in order to glean patient diagnosis
information. As such, the HDP is explored instead, where by the patient data is still
seen as a single dimension dataset, but now is separated into patient corpora. This
then eliminates the need for additional data combination and separation steps that
would be required for the DP-GMM. Additionally, this helps to link formally the
possible combination of the HDP and the BPFA. This also allows for the expansion
of patient data sets to include other information (such as symptoms or time point
data) to improve classification. The downside to the H-PREDICT and HB-PREDICT
methods are that they have higher computational complexity than the Z-PREDICTn
and ZB-PREDICTn methods due to the adaptive learning for diagnosis.
All methods as listed in Tables 7.7 and 7.8 result in the creation of an adaptive
learning framework for immunosignaturing with improved detection and diagnosis
capability. While touched upon briefly in this section, there is still much work to be
done. Possible extensions will be further discussed in the next section.
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Chapter 8
CONCLUSIONS AND FUTURE WORK
8.1 Conclusion
Given the methods summarized in Tables 7.7 and 7.8, we have shown that it is
possible to analyze immunosignaturing data using Bayesian nonparametric adaptive
learning techniques to facilitate the identification and clustering of single disease state
data without the need for a training set or supervised learning techniques, as well as
shown that it is possible to diagnose individuals with multiple disease pathologies.
This is done while maintaining method flexibility to account for varied biological
responses both on an individual level as well as within a patient population. Further-
more, the adaptive framework comprising all previously discussed methods provides
algorithms with a variety of computational complexities. In Table 7.7 the methods,
with the exception of the previously reported naive Bayes method, are presented in
order of increasing complexity. The tradeoff presented is generally that the greater
complexity yields better performing clustering. For example, PREDICT (PCA REso-
lution with DP-GMM for Immunosignature Classification Testing) and B-PREDICT
(Beta PDF REsolution with DP-GMM for Immunosignature Classification Testing)
are the methods with the lowest overhead as they contain the dimensionality reduc-
tion and Dirichlet process Gaussian mixture modeling (DP-GMM) applications only,
and are simultaneously one of the lowest performing methods (60%-76.7%). The
Z-PREDICT (Z-matrix from PCA REsolution and Discovery for Immunosignature
Classification Testing), ZB-PREDICT (Z-matrix from Beta PDF REsolution and-
Discovery for Immunosignature Classification Testing) and Φ-PREDICT (Φ PCA
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REsolution and Discovery for Immunosignature Classification Testing) methods are
the next most computationally intensive methods, but yield some of the best perfor-
mance results (43.3-88%), with the lowest performing method being due to required
user specified significance levels. While Z-PREDICT and ZB-PREDICT yield good
results, they require some additional Z matrix manipulation after the fact. This can
be eliminated by the application of the BIO-PREDICT (BPFA Including prOcess-
ing with PCA REsolution and DP-GMM for Immunosignature Classification Testing)
and BIOB-PREDICT (BPFA Including prOcessing with Beta PDF REsolution with
DP-GMM for Immunosignature Classification Testing) methods, which automate this
step. As such, the BIOB-PREDICT and BIO-PREDICT methods have some of the
best clustering results (66.7%-88%), but are also the most computationally complex.
Inherent in all of these approaches is the assumption that each immunosig-
nature should be grouped in a single cluster. This may be overly restrictive when
considering that patients may have multiple pathologies, or in cases where additional
data, such as disease stage or time point, is required. Furthermore, it would be help-
ful to combine cluster identification, such as disease diagnosis in the case of multiple
diseases, with the method. This then leads to the Z-PREDICTn (Z-matrix from
PCA REsolution and Discovery for Immunosignature Classification Testing up to
n-states) and ZB-PREDICTn (Z-matrix from Beta PDF REsolution and Discovery
for Immunosignature Classification Testing up to n-states) methods. These meth-
ods achieved fairly good results when tested on combination data (65%-100%) with
fairly low error (5%-35%). While these methods do require the adaptive BPFA in
execution, they do not cluster automatically. Additionally, since these methods in-
corporate a training set but this training set is only used in the final comparison
steps of the algorithm outside of the adaptive learning framework, these are consid-
ered semi-supervised. The ability to adaptively classify based on the multi-cluster
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data is then explored, resulting in the H-PREDICT (HDP of PCA REsolution and
Discovery for Immunosignature Classification Testing) and HB-PREDICT (HDP of
Beta PDF REsolution and Discovery for Immunosignature Classification Testing)
methods. While these methods resulted in slightly lower classification results due to
less known user information as compared to the Z-PREDICTn and ZB-PREDICTn
methods, they also extended the adaptive framework to diagnosis capabilities. This
resulted in correct classification in the range of 50%-75% with combined errors in
the range of 12.5%-25%. Additionally, the use of the Z-PREDICTn, ZB-PREDICTn,
H-PREDICT, and HB-PREDICT methods allows for application to multiple different
research problems outside of immunosignaturing as well.
The combination of these methods results in a flexible framework for adaptive
clustering and ultimately diagnosis that is useful both in cases where novel data
point introduction is possible with no known prior information (such as in the case
of a new disease in a population), as well as in cases where cluster identification is
required and multiple cluster membership is desired (such as in the case of multiple
disease presence). This framework is flexible enough to incorporate additional data
outside of immunosignaturing, and even be used for other unrelated problems where
the researcher desires similar outcomes to those discussed here. This then represents
an improved modeling and diagnostic framework.
8.2 Future Work
While this provides a foundation for the use of adaptive methods in immunosig-
naturing and helps to expand the area of latent feature combination clustering, espe-
cially in the case of multi-cluster membership and identification, there is still much
more to be explored in these areas. First, for the single cluster membership case, the
Φ-PREDICT method may be expanded to include adaptive learning clustering, thus
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eliminating the need for user specified thresholds and quantization. This could pos-
sibly help increase the accuracy, as well as determine an amount of membership for
various features, as opposed to the binary case when only the Z matrix is considered.
For dimensionality reduction, other methods may be more appropriate than
simply distribution fitting or PCA. Single distribution parameters may miss multi-
modal embodiments, and PCA supposes that all relevant data is maximized along
the selected orthogonal bases. Other dimensionality reduction schemes may be more
appropriate, or even combinations of these schemes, such as the use of both PCA
and BPF, may result in improved performance. Further, each application involving
the use of the DP-GMM, BPFA, and HDP models may select different priors that
could result in further clustering or diagnosis improvements. The application of dif-
ferent base distributions as well as the exploration of alternate MCMC methods to
improve efficiency are both possible directions. It may also be possible to set up
these improvements as an optimization problem where the previously user specified
parameters, such as innovation parameters, are now optimized in process, rather than
remaining static throughout the estimation steps. Additionally, it may be desireable
to extend the BPFA models to include feature weighting, though some additional
thought is required for the biological representation behind this weigh matrix.
Additional model refinements may also be possible to better represent the bio-
logical mechanisms at play in antibody binding. For instance, this work simplifies the
approach as a first step to include the assumption that only non-competitive effects
are dominant, which may not be the case depending on the antibodies present or the
peptide sequences used. This may be one way to incorporate a weighted model, with
possible negative numbers indicating competitive effects. Additional studies may also
be done to show the biological relationships between diseases, resulting in phylogenic
trees for various diseases. This could be accomplished by doing a comparison between
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model parameters and present features for similarly related diseases and thus extended
to show latent relationships between diseases previously thought unrelated. Further
work may also elect to focus on specific peptides present in various disease states. In
fact, these same methods may be able to be used with minimal modification, with
the exception of transposing the initial input data matrix (i.e. the immunosignature
data). This could help to better understand specific antibodies, and lead to refining
of microarrays for specific diseases.
In the case of multi-cluster membership for a single patient, additional re-
search is also possible. In the most straightforward case, additional data may be used
(such as time course data, symptom data, etc) to show relationships between these
different metrics. Interestingly, this data can be included at a variety of steps in the
algorithms including at the data reduction step as simply another dimension, post-
dimensionality reduction as another dimension, post BPFA as another feature (albeit
not necessarily a latent one), or pre-HDP to create a multidimensional dataset as in-
put. It may also be possible to achieve improved classification results by the adoption
of a different Z matrix modification scheme. The method presented here is related to
a non-normalized dot product, which may not be the most optimal. It is possible that
one could combine this step with the naive Bayes approach but rather than assigning
the datapoint to the top comparison value, simply use the entire set of comparison
values as a cohort input to the HDP. The flexibility of the framework presented here
allows for a variety of methods to be tried and optimized without compromising the
final diagnosis intent in the algorithm. Another possible direction is the use of the
hierarchical BPFA as opposed to a single BPFA dataset, which would then allow for
generalization of input datasets. However, this would require an adjustment in the
Z matrix modification that occurs pre-HDP. This could also be investigated as an
optimization problem with a variety of available input datasets.
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Finally, it is possible to use these methods in a variety of problems outside
of immunosignaturing. These methods would be most helpful in high dimensionality
data situations where there is a desire to adaptively learn, cluster, and classify the
input data. This can included cases where single cluster membership is desired, as
well as cases were more complex classification relationships need to be understood,
such as in the case of multi-cluster assignment.
Given this discussion, there are a variety of directions that can be pursued
using these methods. As such, this work is seen as a solid initiation point with further
classification and computational improvements possible. This can help to further
improve the immunosignaturing platform as well as extend to other cases where there
is a desire to link multi-feature analysis with multi-membership classification.
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